Teleflex (TFX) 10-Q 2 Aug 18 2018 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jul. 01, 2018	Jul. 30, 2018
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jul. 1, 2018
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	Q2
Trading Symbol	TFX
Entity Registrant Name	TELEFLEX INCORPORATED
Entity Central Index Key	96,943
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		45,795,694

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF INCOME (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jul. 01, 2018	Jul. 02, 2017	Jul. 01, 2018	Jul. 02, 2017
Income Statement [Abstract]
Net revenues	$ 609,866	$ 528,613	$ 1,197,096	$ 1,016,494
Cost of goods sold	265,088	238,329	521,048	470,650
Gross profit	344,778	290,284	676,048	545,844
Selling, general and administrative expenses	229,917	158,934	445,254	322,903
Research and development expenses	26,018	20,278	52,045	38,105
Restructuring and impairment charges	55,353	870	58,416	13,815
Income from continuing operations before interest, loss on extinguishment of debt and taxes	33,490	110,202	120,333	171,021
Interest expense	26,649	19,894	52,592	37,620
Interest income	(183)	(161)	(456)	(330)
Loss on extinguishment of debt	0	11	0	5,593
Income from continuing operations before taxes	7,024	90,458	68,197	128,138
Taxes on income from continuing operations	9,576	12,095	15,818	9,426
Income from continuing operations	(2,552)	78,363	52,379	118,712
Operating income (loss) from discontinued operations	94	(566)	1,329	(848)
Tax (benefit) on income (loss) from discontinued operations	38	(206)	20	(309)
Income (loss) from discontinued operations	56	(360)	1,309	(539)
Net income	$ (2,496)	$ 78,003	$ 53,688	$ 118,173
Basic:
Income from continuing operations (in dollars per share)	$ (0.06)	$ 1.74	$ 1.15	$ 2.64
Income (loss) from discontinued operations (in dollars per share)	0.01	(0.01)	0.03	(0.01)
Net income (in dollars per share)	(0.05)	1.73	1.18	2.63
Diluted:
Income from continuing operations (in dollars per share)	(0.06)	1.67	1.12	2.54
Loss from discontinued operations (in dollars per share)	0.01	0	0.03	(0.01)
Net income (in dollars per share)	(0.05)	1.67	1.15	2.53
Dividends per share (in dollars per share)	$ 0.34	$ 0.34	$ 0.68	$ 0.68
Weighted average common shares outstanding
Basic (in shares)	45,581	44,996	45,455	44,945
Diluted (in shares)	45,581	46,818	46,771	46,716

CONDENSED CONSOLIDATED STATEME3

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jul. 01, 2018	Jul. 02, 2017	Jul. 01, 2018	Jul. 02, 2017
Statement of Comprehensive Income [Abstract]
Net (loss) income	$ (2,496)	$ 78,003	$ 53,688	$ 118,173
Other comprehensive income, net of tax:
Foreign currency translation, net of tax of $9,378, $(11,392), $3,505, and $(18,481), for the three and six months periods, respectively	(125,705)	65,685	(44,517)	112,667
Pension and other postretirement benefit plans adjustment, net of tax of $(656), $(465), $(890), and $(997) for the three and six month period, respectively	2,015	704	2,896	1,594
Derivatives qualifying as hedges, net of tax of $100, $(615), $(111) and $(1,170) for the three and six month period, respectively	(329)	3,433	292	5,161
Other comprehensive (loss) income, net of tax:	(124,019)	69,822	(41,329)	119,422
Comprehensive (loss) income	$ (126,515)	$ 147,825	$ 12,359	$ 237,595

CONDENSED CONSOLIDATED STATEME4

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Parenthetical) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jul. 01, 2018	Jul. 02, 2017	Jul. 01, 2018	Jul. 02, 2017
Statement of Comprehensive Income [Abstract]
Foreign currency translation, tax	$ 9,378	$ (11,392)	$ 3,505	$ (18,481)
Pension and other postretirement benefits plans adjustment, tax	(656)	(465)	(890)	(997)
Derivatives qualifying as hedges, tax	$ 100	$ (615)	$ (111)	$ (1,170)

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands	Jul. 01, 2018	Dec. 31, 2017
Current assets
Cash and cash equivalents	$ 346,304	$ 333,558
Accounts receivable, net	359,119	345,875
Inventories, net	405,428	395,744
Prepaid expenses and other current assets	52,105	47,882
Prepaid taxes	19,084	5,748
Assets held for sale	3,239	0
Total current assets	1,185,279	1,128,807
Property, plant and equipment, net	410,979	382,999
Goodwill	2,220,888	2,235,592
Intangible assets, net	2,306,204	2,383,748
Deferred tax assets	2,386	3,810
Other assets	49,585	46,536
Total assets	6,175,321	6,181,492
Current liabilities
Current borrowings	86,875	86,625
Accounts payable	94,834	92,027
Accrued expenses	104,340	96,853
Current portion of contingent consideration	110,454	74,224
Payroll and benefit-related liabilities	89,669	107,415
Accrued interest	6,771	6,165
Income taxes payable	5,597	11,514
Other current liabilities	37,905	9,053
Total current liabilities	536,445	483,876
Long-term borrowings	2,145,468	2,162,927
Deferred tax liabilities	596,434	603,676
Pension and postretirement benefit liabilities	113,083	121,410
Noncurrent liability for uncertain tax positions	12,765	12,296
Noncurrent contingent consideration	132,205	197,912
Other liabilities	204,940	168,864
Total liabilities	3,741,340	3,750,961
Commitments and contingencies
Total shareholders' equity	2,433,981	2,430,531
Total liabilities and shareholders' equity	$ 6,175,321	$ 6,181,492

CONDENSED CONSOLIDATED STATEME6

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jul. 01, 2018	Jul. 02, 2017
Cash flows from operating activities of continuing operations:
Net (loss) income	$ 53,688	$ 118,173
Adjustments to reconcile net income to net cash provided by operating activities:
(Income) loss from discontinued operations	(1,309)	539
Depreciation expense	29,527	28,084
Amortization expense of intangible assets	75,008	41,375
Amortization expense of deferred financing costs and debt discount	2,368	2,825
Loss on extinguishment of debt	0	5,593
Fair value step up of acquired inventory sold	0	10,442
Changes in contingent consideration	34,618	(237)
Impairment of long-lived assets	1,865	0
Stock-based compensation	10,737	9,534
Deferred income taxes, net	4,821	(8,779)
Other	(3,669)	(3,300)
Changes in operating assets and liabilities, net of effects of acquisitions and disposals:
Accounts receivable	(15,886)	5,071
Inventories	(15,017)	(12,187)
Prepaid expenses and other current assets	(3,611)	4
Accounts payable, accrued expenses and other liabilities	38,112	6,541
Income taxes receivable and payable, net	(29,668)	(5,988)
Net cash provided by operating activities from continuing operations	181,584	197,690
Cash flows from investing activities of continuing operations:
Expenditures for property, plant and equipment	(38,004)	(36,833)
Proceeds from sale of assets	0	6,332
Payments for businesses and intangibles acquired, net of cash acquired	(22,450)	(993,459)
Net cash used in investing activities from continuing operations	(60,454)	(1,023,960)
Cash flows from financing activities of continuing operations:
Proceeds from new borrowings	0	1,194,500
Reduction in borrowings	(18,500)	(228,273)
Debt extinguishment, issuance and amendment fees	(188)	(19,114)
Net proceeds from share based compensation plans and the related tax impacts	9,800	1,305
Payments for contingent consideration	(62,574)	(153)
Dividends paid	(30,938)	(30,590)
Net cash provided by (used in) financing activities from continuing operations	(102,400)	917,675
Cash flows from discontinued operations:
Net cash used in operating activities	(464)	(961)
Net cash used in discontinued operations	(464)	(961)
Effect of exchange rate changes on cash and cash equivalents	(5,520)	41,981
Net increase in cash and cash equivalents	12,746	132,425
Cash and cash equivalents at the beginning of the period	333,558	543,789
Cash and cash equivalents at the end of the period	346,304	676,214
Non cash investing activities of continuing operations:
Property, plant and equipment additions due to build-to-suit lease transaction	28,147	0
Non cash financing activities of continuing operations:
Settlement and exchange of convertible notes with common or treasury stock	0	983
Acquisition of treasury stock associated with settlement and exchange of convertible note hedge and warrant agreements	$ 36,877	$ 19,361

CONDENSED CONSOLIDATED STATEME7

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (Unaudited) - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock	Additional Paid In Capital	Retained Earnings	Accumulated Other Comprehensive Loss	Treasury Stock
Beginning Balance at Dec. 31, 2016					$ (438,717)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net (loss) income	$ 118,173
Other comprehensive income	119,422
Ending Balance at Jul. 02, 2017					(319,295)
Beginning Balance (in shares) at Dec. 31, 2017		46,871				1,704
Beginning Balance at Dec. 31, 2017	2,430,531	$ 46,871	$ 591,721	$ 2,285,886	(265,091)	$ (228,856)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net (loss) income	53,688			53,688
Cash dividends ($0.68 per share)	(30,938)			(30,938)
Other comprehensive income	(41,329)				(41,329)
Settlements of warrants (in shares)						(272)
Settlements of warrants	(26)		(36,903)			$ 36,877
Shares issued under compensation plans (in shares)		(211)				(45)
Shares issued under compensation plans	18,422	$ 211	$ 14,984			$ 3,227
Deferred compensation (in shares)			(235)			(8)
Deferred compensation	557					$ 322
Ending Balance (in shares) at Jul. 01, 2018		47,082				1,379
Ending Balance at Jul. 01, 2018	$ 2,433,981	$ 47,082	$ 570,037	$ 2,311,712	$ (306,420)	$ (188,430)

CONDENSED CONSOLIDATED STATEME8

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (Parenthetical) - $ / shares	3 Months Ended		6 Months Ended
	Jul. 01, 2018	Jul. 02, 2017	Jul. 01, 2018	Jul. 02, 2017
Statement of Stockholders' Equity [Abstract]
Dividends per share (in dollars per share)	$ 0.34	$ 0.34	$ 0.68	$ 0.68

Basis of presentation

Basis of presentation	6 Months Ended
	Jul. 01, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of presentation	Note 1 — Basis of presentation The accompanying unaudited condensed consolidated financial statements of Teleflex Incorporated and its subsidiaries (“we,” “us,” “our,” “Teleflex” and the “Company”) are prepared on the same basis as its annual consolidated financial statements. In the opinion of management, the financial statements reflect all adjustments, which are of a normal recurring nature, necessary for the fair presentation of financial statements for interim periods in accordance with accounting principles generally accepted in the United States of America ("GAAP") and with Rule 10-01 of Securities and Exchange Commission ("SEC") Regulation S-X, which sets forth the instructions for financial statements included in Form 10-Q. The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. The results of operations for the periods reported are not necessarily indicative of those that may be expected for a full year. In accordance with applicable accounting standards and as permitted by Rule 10-01 of Regulation S-X, the accompanying condensed consolidated financial statements do not include all of the information and footnote disclosures that are required to be included in the Company's annual consolidated financial statements. Accordingly, the Company's quarterly condensed consolidated financial statements should be read in conjunction with the Company's consolidated financial statements included in its Annual Report on Form 10-K for the year ended December 31, 2017 .

New accounting standards

New accounting standards	6 Months Ended
	Jul. 01, 2018
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]
New accounting standards	New accounting standards In May 2014, the Financial Accounting Standards Board ("FASB"), in a joint effort with the International Accounting Standards Board ("IASB"), issued new accounting guidance to clarify the principles for recognizing revenue. This new guidance, as amended by additional guidance issued in 2015 and 2016, is encompassed in FASB Accounting Standards Codification Topic 606, Revenue from Contracts with Customers (“ASC 606”) and is designed to enhance the comparability of revenue recognition practices across entities, industries, jurisdictions and capital markets, and affects any entity that enters into contracts with customers or enters into contracts for the transfer of nonfinancial assets, unless those contracts are within the scope of other standards. The new guidance establishes principles for reporting information to users of financial statements about the nature, amount, timing, and uncertainty of revenue and cash flows arising from an entity's contracts with customers. The core principle of the new guidance is that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods and services. The Company adopted the new standard on January 1, 2018, applying the modified retrospective method to all of its contracts; as a result, the Company recognized the cumulative effect of adopting the guidance as a $1.2 million increase to the Company's opening balance of retained earnings on the adoption date. In addition, in connection with its adoption of the new guidance, the Company reclassified the reserve for product returns from a reduction of receivables to a liability. The reserve for returns and allowances was $4.2 million at July 1, 2018. The adoption of this guidance did not have a material impact on the Company's consolidated results of operations, cash flows and financial position. Additional information and disclosures required by this new standard are contained in Note 3. In February 2016, the FASB issued guidance that will change the requirements for accounting for leases. Under the new guidance, lessees (including lessees under both leases classified as finance leases, which are to be classified based on criteria similar to that applicable to capital leases under current guidance, and leases classified as operating leases) will recognize a right-to-use asset and a lease liability on the balance sheet, initially measured as the present value of lease payments under the lease. Under current guidance, operating leases are not recognized on the balance sheet. The standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted. The new standard must be adopted using a modified retrospective transition approach for leases with an option to elect a package of practical expedients. Further, companies can elect to apply the transition approach either for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements or those existing at, or entered into after, the adoption date. The Company is currently evaluating this guidance to determine its impact on the Company’s consolidated results of operations, cash flows and financial position. In October 2016, the FASB issued new guidance requiring companies to recognize the income tax effects of intra-entity sales and transfers of assets, other than inventory, in the income statement as income tax expense (or benefit) in the period in which the transfer occurs. Previously, recognition was prohibited until the assets were sold to an outside party or otherwise utilized. The Company adopted the new standard on January 1, 2018 using the modified retrospective method of adoption; as a result, the Company recognized the cumulative effect of adopting the guidance as a $1.8 million increase to the Company's opening balance of retained earnings on the adoption date. The adoption of this guidance did not have a material impact on the Company's consolidated results of operations, cash flows and financial position. In March 2017, the FASB issued guidance for employers that sponsor defined benefit pension or other postretirement benefit plans. The guidance requires that these employers disaggregate specified components of net periodic pension cost and net periodic postretirement benefit cost (collectively, "net benefit cost"). Specifically, the guidance generally requires employers to present in the income statement the service cost component of net benefit cost in the same line item or items as other compensation costs arising from services rendered by the pertinent employees during the period. The other components of net benefit cost are required to be presented in the income statement separately from the service cost component and outside a subtotal of income from operations. The Company adopted this guidance on January 1, 2018; the impact was not material to the consolidated financial statements. In August 2017, the FASB issued guidance with the objective of improving the financial reporting of hedging relationships to better portray the economic results of an entity's risk management activities in its financial statements. The new guidance provides for changes to current designation and measurement guidance for qualifying hedging relationships and to the method of presenting hedge results. In addition, the new guidance includes certain targeted improvements to ease the application of current guidance related to the assessment of hedge effectiveness. The new guidance is effective for reporting periods beginning after December 15, 2018. Early adoption is permitted. The Company is currently evaluating the impact of the adoption of this guidance on its consolidated results of operations and financial position. In February 2018, the FASB issued new guidance to address a narrow-scope financial reporting issue that arose as a consequence of the Tax Cuts and Jobs Act ("the TCJA"). Existing guidance requires that deferred tax liabilities and assets be adjusted for a change in tax laws or rates with the effect included in income from continuing operations in the reporting period that includes the enactment date. The guidance is applicable even in situations in which the related income tax effects of items in accumulated other comprehensive income were originally recognized in other comprehensive income (rather than in net income), such as amounts related to benefit plans and hedging activity. As a result, the tax effects of items within accumulated other comprehensive income (referred to as stranded tax effects) do not reflect the appropriate tax rate. The new guidance permits for a reclassification of these amounts to retained earnings, thereby eliminating the stranded tax effects. The new guidance also requires certain disclosures about the stranded tax effects. The guidance is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted for reporting periods for which financial statements have not yet been issued. The new guidance can be applied either in the period of adoption or retrospectively to each period (or periods) in which the effect of the change in the U.S. federal corporate income tax rate in the TCJA is recognized. The Company is currently evaluating the impact this guidance will have on its consolidated financial statements. From time to time, new accounting guidance is issued by the FASB or other standard setting bodies that is adopted by the Company as of the effective date or, in some cases where early adoption is permitted, in advance of the effective date. The Company has assessed the recently issued guidance that is not yet effective and, unless otherwise indicated above, believes the new guidance will not have a material impact on the its consolidated results of operations, cash flows or financial position.

Net revenues

Net revenues	6 Months Ended
	Jul. 01, 2018
Deferred Revenue Disclosure [Abstract]
Net revenues	Net revenues The Company primarily generates revenue from the sale of medical devices including single use disposable devices and, to a lesser extent, reusable devices, instruments and capital equipment. Revenue is recognized when obligations under the terms of a contract with the Company’s customer are satisfied; this occurs upon the transfer of control of the products. Generally, transfer of control to the customer occurs at the point in time when the Company’s products are shipped from the manufacturing or distribution facility. For the Company’s OEM segment, most revenue is recognized over time because the OEM segment generates revenue from the sale of custom products that have no alternative use and the Company has an enforceable right to payment for performance completed to date. The Company markets and sells products through its direct sales force and distributors to customers within the following end markets: (1) hospitals and healthcare providers; (2) other medical device manufacturers; and (3) home care providers such as pharmacies, which comprised 87% , 9% and 4% of consolidated net revenues, respectively, for the six months ended July 1, 2018 . Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring goods. With respect to the custom products sold in the OEM segment, revenue is measured using the units produced output method. Payment is generally due 30 days from the date of invoice. The Company has made the following accounting policy elections and elected to use certain practical expedients, as permitted by the FASB, in applying ASC 606: (1) the Company accounts for amounts collected from customers for sales and other taxes, net of related amounts remitted to tax authorities; (2) the Company does not adjust the promised amount of consideration for the effects of a significant financing component because, at contract inception, the Company expects the period between the time when the Company transfers a promised good or service to the customer and the time when the customer pays for that good or service will be one year or less; (3) the Company expenses costs to obtain a contract as they are incurred if the expected period of benefit, and therefore the amortization period, is one year or less; (4) the Company accounts for shipping and handling activities that occur after control transfers to the customer as a fulfillment cost rather than an additional promised service; (5) the Company classifies shipping and handling costs within cost of goods sold; and (6) with respect to the OEM segment, the Company has applied the practical expedient to exclude disclosure of remaining performance obligations as the contracts typically have a term of one year or less. The amount of consideration the Company receives and revenue the Company recognizes varies as a result of changes in customer sales incentives, including discounts and rebates, and returns offered to customers. The estimate of revenue is adjusted upon the earlier of the following events: (i) the most likely amount of consideration expected to be received changes or (ii) the consideration becomes fixed. The Company’s policy is to accept returns only in cases in which the product is defective and covered under the Company’s standard warranty provisions. When the Company gives customers the right to return products, the Company estimates the expected returns based on an analysis of historical experience. The reserve for returns and allowances was $4.2 million and $4.5 million as of July 1, 2018 and July 2, 2017 , respectively. In estimating customer rebates, the Company considers the lag time between the point of sale and the payment of the customer’s rebate claim, customer-specific trend analyses, contractual commitments, including stated rebate rates, historical experience with respect to specific customers and other relevant information as the Company has a history of providing similar rebates on similar products to similar customers. The reserve for customer incentive programs, including customer rebates, was $13.6 million and $10.7 million at July 1, 2018 and July 2, 2017 , respectively. The Company expects the amounts subject to the reserve as of July 1, 2018 to be paid within 90 days subsequent to period-end. The following table disaggregates revenue by global product category for the three and six months ended July 1, 2018 and July 2, 2017 . Three Months Ended Six Months Ended July 1, 2018 July 2, 2017 July 1, 2018 July 2, 2017 Revenue by global product category (1) (2) (Dollars in thousands) Vascular access $ 140,604 $ 133,323 $ 284,845 $ 263,345 Anesthesia 89,810 85,938 175,229 167,143 Interventional 77,179 68,425 148,858 112,391 Surgical 90,489 90,740 176,139 178,044 Interventional urology 47,674 — 89,974 — OEM 52,594 45,132 98,448 88,478 Other (3) 111,516 105,055 223,603 207,093 Net revenues $ 609,866 $ 528,613 $ 1,197,096 $ 1,016,494 (1) The product categories listed above are presented on a global basis; in contrast, the Company’s North American reportable segments generally are defined largely based on the particular products sold by the segments, and its non-North American reportable segments are defined exclusively based on the geographic location of segment operations (with the exception of the Original Equipment and Development Services ("OEM") reportable segment, which operates globally). The Company’s EMEA and Asia reportable segments, as well as its Latin America operating segment, include net revenues from each of the product categories listed above. (2) The methodology used to determine the product revenues included within certain of the product categories listed in the table above differs from the methodology used to recognize revenues in our reportable segments, including the similarly named North American reportable segments. The differences are due to the fact that segment classification generally is determined based on the call point within the customer's organization from which the purchase order resulting in the sales originated, while the classification of products within the product categories listed in the table above includes all sales of products within the listed product category, regardless of the call point within the customer's organization from which the sales originated. (3) Other revenues in the table above comprise the Company’s respiratory, urology and cardiac product categories.

Acquisitions

Acquisitions	6 Months Ended
	Jul. 01, 2018
Business Combinations [Abstract]
Acquisitions	Acquisitions On June 21, 2018, the Company acquired certain assets of QT Vascular LTD ("QT Vascular"), a medical device company that developed and marketed coronary balloon catheters, which complement the Company's interventional product portfolio. The aggregate consideration transferred for the assets, which primarily consisted of intellectual property, was $20.6 million . 2017 Acquisitions During 2017, the Company completed several acquisitions; the largest of which were NeoTract, Inc. ("NeoTract") and Vascular Solutions, Inc. ("Vascular Solutions"), which are summarized below. The fair value of the consideration transferred for the 2017 acquisitions was $2.0 billion . NeoTract On October 2, 2017, the Company acquired NeoTract, a medical device company that developed and commercialized the UroLift System, a minimally invasive medical device for treating lower urinary tract symptoms due to benign prostatic hyperplasia, or BPH. The Company made initial payments of $725.6 million in cash less a favorable working capital adjustment of $1.4 million . Additionally, the estimated fair value of contingent consideration related to NeoTract sales-based milestones as of July 1, 2018 was $227.7 million . The contingent consideration liability represents the estimated fair value of the Company’s obligations, under the acquisition agreement, to make payments of up to $ 375 million in the aggregate if specified sales goals through the end of 2020 are achieved. The Company made an additional payment of $75.0 million ( $64.2 million of which was paid during the second quarter 2018 and $10.8 million of which was paid during the first week of the third quarter 2018) as a result of the achievement of a sales goal for the period from January 1, 2018 to April 30, 2018. Financial information of NeoTract is primarily presented within the Interventional Urology North America operating segment, which is included in the "all other" category in the Company's presentation of segment information. The Company is continuing to evaluate the initial purchase price allocations in connection with its acquisition of NeoTract, and further adjustments may be necessary as a result of the Company's assessment of additional information related to the fair values of the assets acquired and liabilities assumed, primarily deferred tax liabilities, certain intangible assets and goodwill. Vascular Solutions On February 17, 2017, the Company acquired Vascular Solutions, a medical device company that developed and marketed products for use in minimally invasive coronary and peripheral vascular procedures. The aggregate consideration paid by the Company in connection with the acquisition was $975.5 million . Pro forma combined financial information The following unaudited pro forma combined financial information for the three and six months ended July 2, 2017 gives effect to the Vascular Solutions and NeoTract acquisitions as if they had occurred on January 1, 2016. The pro forma information is presented for informational purposes only and is not necessarily indicative of the results of operations that actually would have occurred under the ownership and management of the Company. Three Months Ended Six Months Ended July 2, 2017 July 2, 2017 (Dollars and shares in thousands, except per share) Net revenue $ 558,836 $ 1,092,154 Net income $ 66,726 $ 103,833 Basic earnings per common share: Net income $ 1.48 $ 2.31 Diluted earnings per common share: Net income $ 1.43 $ 2.22 Weighted average common shares outstanding: Basic 44,996 44,945 Diluted 46,818 46,716 The unaudited pro forma combined financial information presented above includes the accounting effects of the Vascular Solutions and NeoTract acquisitions, including, to the extent applicable, amortization charges from acquired intangible assets; adjustments for depreciation of property, plant and equipment; interest expense; and the related tax effects.

Restructuring charges and impai

Restructuring charges and impairment charges	6 Months Ended
	Jul. 01, 2018
Restructuring and Related Activities [Abstract]
Restructuring charges and impairment charges	Note 5 — Restructuring and impairment charges The following tables provide information regarding restructuring and impairment charges recognized by the Company for the three and six months ended July 1, 2018 and July 2, 2017 : Three Months Ended July 1, 2018 Termination benefits Other costs (2) Total (Dollars in thousands) 2018 Footprint realignment plan $ 52,345 $ 129 $ 52,474 Other restructuring programs (1) 574 440 1,014 Restructuring charges $ 52,919 $ 569 $ 53,488 Long-lived asset impairment charge — 1,865 1,865 Restructuring and impairment charges $ 52,919 $ 2,434 $ 55,353 Three Months Ended July 2, 2017 Termination benefits Other costs (2) Total (Dollars in thousands) Restructuring charges (3) $ 612 $ 258 $ 870 Six Months Ended July 1, 2018 Termination benefits Other costs (2) Total (Dollars in thousands) 2018 Footprint realignment plan $ 52,345 $ 129 $ 52,474 2016 Footprint realignment plan 2,199 291 2,490 Other restructuring programs (4) 1,032 555 1,587 Restructuring charges $ 55,576 $ 975 $ 56,551 Long-lived asset impairment charge — 1,865 1,865 Restructuring and impairment charges $ 55,576 $ 2,840 $ 58,416 Six Months Ended July 2, 2017 Termination benefits Other costs (2) Total (Dollars in thousands) Vascular Solutions integration program $ 4,853 $ 34 $ 4,887 2017 EMEA restructuring program 6,536 — 6,536 2016 Footprint realignment plan 825 76 901 Other restructuring programs (5) 1,147 344 1,491 Restructuring charges $ 13,361 $ 454 $ 13,815 (1) Other restructuring programs include the 2016 and 2014 Footprint realignment plans, the Vascular Solutions integration program and the 2017 EMEA restructuring program as well as the other 2016 restructuring programs. (2) Other costs include facility closure, contract termination, and other exit costs. (3) Restructuring charges include charges related to the Vascular Solutions integration program, 2017 EMEA restructuring program, the 2016 and 2014 footprint realignment plans, the 2017 Pyng integration program and the 2016 Other Restructuring programs. The Company committed to the 2017 Pyng integration program, which relates to the integration of Pyng Medical Corp. (“Pyng”) into the Company, during the second quarter of 2017, following the Company’s acquisition of Pyng in April 2017. (4) Other restructuring programs include the 2014 Footprint realignment plan, Vascular Solutions integration program, the 2017 EMEA restructuring program and the other 2016 restructuring programs. (5) Other restructuring programs include the 2014 Footprint realignment plan, the 2017 Pyng integration program and the 2016 Other Restructuring programs. 2018 Footprint Realignment Plan On May 1, 2018, the Company initiated a restructuring plan involving the relocation of certain European manufacturing operations to an existing lower-cost location, the outsourcing of certain of the Company’s European distribution operations, and related workforce reductions (the “2018 Footprint realignment plan"). These actions are expected to be substantially completed by the end of 2024. The following table provides a summary of the Company’s cost estimates by major type of expense associated with the 2018 Footprint realignment plan: Type of expense Total estimated amount expected to be incurred Termination benefits $60 million to $70 million Other exit costs (1) $2 million to $4 million Restructuring charges $62 million to $74 million Restructuring related charges (2) $40 million to $59 million Total restructuring and restructuring related charges $102 million to $133 million (1) Includes contract termination, facility closure, employee relocation, equipment relocation and outplacement costs. (2) Consists of pre-tax charges related to accelerated depreciation and other costs directly related to the plan, primarily project management costs and costs to transfer manufacturing operations to the new location, as well as a charge associated with the Company’s exit from the facilities that is expected to be imposed by the taxing authority in the affected jurisdiction. Excluding this tax charge, substantially all of the charges are expected to be recognized within costs of goods sold. In addition to the restructuring charges shown in the tables above, the Company recorded restructuring related charges with respect to the 2018 Footprint realignment plan of $1.0 million for the three and six months ended July 1, 2018 within cost of goods sold. As of July 1, 2018, the Company has a restructuring reserve of $51.4 million related to this plan, all of which related to termination benefits. 2016 Footprint Realignment Plan In 2016, the Company initiated a restructuring plan (the “2016 Footprint realignment plan") involving the relocation of certain manufacturing operations, the relocation and outsourcing of certain distribution operations and a related workforce reduction at certain of the Company's facilities. These actions commenced in the first quarter of 2016 and are expected to be substantially completed by the end of 2018. In addition to the restructuring charges shown in the tables above, the Company recorded restructuring related charges with respect to the 2016 Footprint realignment plan of $2.0 million and $3.3 million for the three and six months ended July 1, 2018 and $2.0 million and $4.1 million for the three and six months ended July 2, 2017 , respectively. The majority of these restructuring related charges in both periods constituted accelerated depreciation and other costs arising principally as a result of the transfer of manufacturing operations to new locations. The Company estimates that it will incur aggregate pre-tax restructuring and restructuring related charges in connection with the 2016 Footprint realignment plan of approximately $43 million . As of July 1, 2018 , the Company has incurred aggregate restructuring charges in connection with the 2016 Footprint realignment plan of $17.1 million . Additionally, as of July 1, 2018 , the Company has incurred aggregate restructuring related charges of $18.0 million with respect to the 2016 Footprint realignment plan, consisting of accelerated depreciation and certain other costs that principally resulted from the transfer of manufacturing operations to new locations. The restructuring related charges primarily were included in cost of goods sold. As of July 1, 2018 , the Company has a restructuring reserve of $6.3 million related to this plan, all of which related to termination benefits. 2014 Footprint Realignment Plan In 2014, the Company initiated a restructuring plan (“the 2014 Footprint realignment plan”) involving the consolidation of operations and a related reduction in workforce at certain facilities, and the relocation of manufacturing operations from certain higher-cost locations to existing lower-cost locations. These actions commenced in the second quarter 2014 and are expected to be substantially completed by the end of the first half of 2020. The Company estimates that it will incur aggregate pre-tax restructuring and restructuring related charges in connection with the 2014 Footprint realignment plan of approximately $46 million to $51 million . In addition to the restructuring charges set forth in the tables above, the Company recorded restructuring related charges with respect to the 2014 Footprint realignment plan of $0.6 million and $1.0 million for the three and six months ended July 1, 2018 , respectively, and $0.5 million and $ 2.1 million for the three and six months ended July 2, 2017 , respectively. The majority of these restructuring related charges in both periods constituted accelerated depreciation and other costs arising principally as a result of the transfer of manufacturing operations to new locations. As of July 1, 2018 , the Company has incurred restructuring charges in connection with the 2014 Footprint realignment plan aggregating to $12.2 million . Additionally, as of July 1, 2018 , the Company has incurred restructuring related charges aggregating to $27.9 million related to the 2014 Footprint realignment plan, consisting of accelerated depreciation and certain other costs that principally resulted from the transfer of manufacturing operations from the existing locations to new locations. These restructuring related charges primarily were included in cost of goods sold. As of July 1, 2018 , the Company has a restructuring reserve of $3.9 million in connection with the plan, all of which related to termination benefits. As the restructuring programs progress, management will reevaluate the estimated expenses and charges set forth above, and may revise its estimates, as appropriate, consistent with GAAP. For a description of the Company's restructuring programs, see Note 4 to the Company's consolidated financial statements included in its annual report on Form 10-K for the year ended December 31, 2017. Restructuring charges by reportable operating segment, and by all other operating segments in the aggregate, for the three and six months ended July 1, 2018 and July 2, 2017 are set forth in the following table: Three Months Ended Six Months Ended July 1, 2018 July 2, 2017 July 1, 2018 July 2, 2017 (Dollars in thousands) Vascular North America $ 202 $ 353 $ 523 $ 1,081 Interventional North America 362 191 907 4,406 Anesthesia North America 91 564 125 811 EMEA 52,539 (412 ) 52,790 7,115 All other 294 174 2,206 402 Restructuring charges $ 53,488 $ 870 $ 56,551 $ 13,815

Inventories, net

Inventories, net	6 Months Ended
	Jul. 01, 2018
Inventory Disclosure [Abstract]
Inventories, net	Note 6 — Inventories, net Inventories as of July 1, 2018 and December 31, 2017 consisted of the following: July 1, 2018 December 31, 2017 (Dollars in thousands) Raw materials $ 103,005 $ 98,451 Work-in-process 63,386 62,381 Finished goods 239,037 234,912 Inventories, net $ 405,428 $ 395,744

Goodwill and other intangible a

Goodwill and other intangible assets, net	6 Months Ended
	Jul. 01, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and other intangible assets, net	Note 7 — Goodwill and other intangible assets, net The following table provides information relating to changes in the carrying amount of goodwill by reportable operating segment, and by all other operating segments in the aggregate, for the six months ended July 1, 2018 : Vascular Interventional North America Anesthesia Surgical EMEA Asia OEM All Total (Dollars in thousands) December 31, 2017 $ 264,869 $ 433,049 $ 157,289 $ 250,912 $ 494,548 $ 209,200 $ 4,883 $ 420,842 $ 2,235,592 Goodwill related to acquisitions — 422 — — 9 3 — 145 579 Currency translation adjustment — (1,938 ) (395 ) — (9,836 ) (2,352 ) — (762 ) (15,283 ) July 1, 2018 $ 264,869 $ 431,533 $ 156,894 $ 250,912 $ 484,721 $ 206,851 $ 4,883 $ 420,225 $ 2,220,888 The Company's gross carrying amount of, and accumulated amortization relating to, intangible assets as of July 1, 2018 and December 31, 2017 were as follows: Gross Carrying Amount Accumulated Amortization July 1, 2018 December 31, 2017 July 1, 2018 December 31, 2017 (Dollars in thousands) Customer relationships $ 1,016,254 $ 1,023,837 $ (302,216 ) $ (281,263 ) In-process research and development 29,763 34,672 — — Intellectual property 1,295,555 1,287,487 (296,217 ) (258,580 ) Distribution rights 23,570 23,697 (17,417 ) (16,996 ) Trade names 568,227 571,510 (29,244 ) (22,069 ) Non-compete agreements 23,507 23,429 (5,578 ) (1,976 ) $ 2,956,876 $ 2,964,632 $ (650,672 ) $ (580,884 )

Financial instruments

Financial instruments	6 Months Ended
	Jul. 01, 2018
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Financial instruments	Note 8 — Financial instruments Foreign Currency Forward Contracts The Company uses derivative instruments for risk management purposes. Foreign currency forward contracts designated as cash flow hedges are used to manage exposure related to foreign currency transactions. Foreign currency forward contracts not designated as hedges for accounting purposes are used to manage exposure related to near term foreign currency denominated monetary assets and liabilities. For the three and six months ended July 1, 2018 the Company recognized a loss related to non-designated foreign currency forward contracts of $1.4 million and $0.7 million , respectively. For the three and six ended July 2, 2017 , the Company recognized a loss related to non-designated foreign currency forward contracts of $2.3 million and $3.1 million , respectively. The following table presents the locations in the condensed consolidated balance sheet and fair value of derivative financial instruments as of July 1, 2018 and December 31, 2017 : July 1, 2018 December 31, 2017 Fair Value (Dollars in thousands) Asset derivatives: Designated foreign currency forward contracts $ 1,513 $ 914 Non-designated foreign currency forward contracts 441 307 Prepaid expenses and other current assets $ 1,954 $ 1,221 Total asset derivatives $ 1,954 $ 1,221 Liability derivatives: Designated foreign currency forward contracts $ 759 $ 1,373 Non-designated foreign currency forward contracts 102 53 Other current liabilities $ 861 $ 1,426 Total liability derivatives $ 861 $ 1,426 The total notional amount for all open foreign currency forward contracts designated as cash flow hedges as of July 1, 2018 and December 31, 2017 was $113.8 million and $88.5 million , respectively. The total notional amount for all open non-designated foreign currency forward contracts as of July 1, 2018 and December 31, 2017 was $110.5 million and $110.6 million , respectively. All open foreign currency forward contracts as of July 1, 2018 have durations of twelve months or less. There was no ineffectiveness related to the Company’s cash flow hedges during the three and six months ended July 1, 2018 and July 2, 2017 . Concentration of Credit Risk Concentrations of credit risk with respect to trade accounts receivable are generally limited due to the Company’s large number of customers and their diversity across many geographic areas. However, a portion of the Company’s trade accounts receivable outside the United States include sales to government-owned or supported healthcare systems in several countries, which are subject to payment delays. Payment is dependent upon the creditworthiness of the healthcare systems in those countries and the financial stability of those countries' economies. Certain of the Company’s customers, particularly in Greece, Italy, Spain and Portugal, have extended or delayed payments for products and services already provided, raising collectability concerns regarding the Company’s accounts receivable from these customers. As a result, the Company continues to closely monitor the allowance for doubtful accounts with respect to these customers. The following table provides information regarding the Company's allowance for doubtful accounts, the aggregate net current and long-term trade accounts receivable related to customers in Greece, Italy, Spain and Portugal and the percentage of the Company’s total net current and long-term trade accounts receivable represented by these customers' trade accounts receivable at July 1, 2018 and December 31, 2017 : July 1, 2018 December 31, 2017 (Dollars in thousands) Allowance for doubtful accounts (1) $ 9,525 $ 10,255 Current and long-term trade accounts receivable, net in Greece, Italy, Spain and Portugal (2) $ 52,569 $ 49,054 Percentage of total net current and long-term trade accounts receivable - Greece, Italy, Spain and Portugal 15.0 % 14.6 % (1) The current portion of the allowance for doubtful accounts was $3.6 million and $3.5 million as of July 1, 2018 and December 31, 2017 , respectively, and was recognized in accounts receivable, net. (2) The long-term portion of trade accounts receivable, net from customers in Greece, Italy, Spain and Portugal at July 1, 2018 and December 31, 2017 was $3.5 million and $3.3 million , respectively. For the six months ended July 1, 2018 and July 2, 2017 , net revenues from customers in Greece, Italy, Spain and Portugal were $75.7 million and $64.5 million , respectively.

Fair value measurement

Fair value measurement	6 Months Ended
	Jul. 01, 2018
Fair Value Disclosures [Abstract]
Fair value measurement	Fair value measurement For a description of the fair value hierarchy, see Note 10 to the Company’s consolidated financial statements included in its Annual Report on Form 10-K for the year ended December 31, 2017 . The following tables provide information regarding the Company's financial assets and liabilities that are measured at fair value on a recurring basis as of July 1, 2018 and December 31, 2017 : Total carrying Quoted prices in active Significant other Significant (Dollars in thousands) Investments in marketable securities $ 9,272 $ 9,272 $ — $ — Derivative assets 1,954 — 1,954 — Derivative liabilities 861 — 861 — Contingent consideration liabilities 242,659 — — 242,659 Total carrying Quoted prices in active Significant other Significant (Dollars in thousands) Investments in marketable securities $ 9,045 $ 9,045 $ — $ — Derivative assets 1,221 — 1,221 — Derivative liabilities 1,426 — 1,426 — Contingent consideration liabilities 272,136 — — 272,136 There were no transfers of financial assets or liabilities reported at fair value among Level 1, Level 2 or Level 3 within the fair value hierarchy during the six months ended July 1, 2018 . Valuation Techniques The Company’s financial assets valued based upon Level 1 inputs are comprised of investments in marketable securities held in trust, which are available to satisfy benefit obligations under Company benefit plans and other arrangements. The investment assets of the trust are valued using quoted market prices. The Company’s financial assets and liabilities valued based upon Level 2 inputs are comprised of foreign currency forward contracts. The Company uses foreign currency forward contracts to manage foreign currency transaction exposure as well as exposure to foreign currency denominated monetary assets and liabilities. The Company measures the fair value of the foreign currency forward contracts by calculating the amount required to enter into offsetting contracts with similar remaining maturities as of the measurement date, based on quoted market prices, and taking into account the creditworthiness of the counterparties. The Company’s financial liabilities valued based upon Level 3 inputs are comprised of contingent consideration arrangements pertaining to the Company’s acquisitions, which are discussed immediately below. Contingent consideration As of July 1, 2018 , the Company estimates that contingent consideration payments will occur in 2018 through 2029, and the maximum amount of undiscounted payments the Company could make under contingent consideration arrangements is $335.2 million . The contingent consideration liabilities, which primarily consist of Company obligations payable if specified net sales goals are achieved, are remeasured to fair value each reporting period using assumptions including estimated revenues (based on internal operational budgets and long-range strategic plans), discount rates, probability of payment and projected payment dates. The contingent consideration fair value measurement is based on significant inputs not observable in the market and therefore constitute Level 3 inputs within the fair value hierarchy. The contingent consideration liability related to the NeoTract acquisition represents the estimated fair value of the Company's obligations to make payments of up to $375 million in the aggregate if specified sales goals are achieved. Specifically, the payments are based on net sales (as defined in the NeoTract acquisition agreement) for the periods from January 1, 2018 through April 30, 2018 and the years ended December 31, 2018, 2019 and 2020. The Company made payments of $75.0 million ( $64.2 million of which was paid during the second quarter 2018 and $10.8 million of which was paid during the first week of the third quarter 2018) as a result of the achievement of a sales goal for the period from January 1, 2018 to April 30, 2018. The fair value of the contingent consideration related to the NeoTract acquisition was estimated using a Monte Carlo valuation approach, which simulates future revenues during the earn out-period using management's best estimates. The Company determines the value of its other contingent consideration liabilities based on a probability-weighted discounted cash flow analysis. Increases in projected revenues and probabilities of payment may result in significantly higher fair value measurements; decreases in these items may have the opposite effect. Increases in the discount rates may result in significantly lower fair value measurements; decreases in these items may have the opposite effect. The table below provides additional information regarding the valuation technique and inputs used in determining the fair value of contingent consideration recognized in connection with the NeoTract acquisition. Valuation Technique Unobservable Input Range Contingent consideration Monte Carlo simulation Revenue volatility 22.3 % Risk free rate Cost of debt structure Projected year of payment 2018 - 2021 The following table provides information regarding changes, during the six months ended July 1, 2018 , in Level 3 financial liabilities related to contingent consideration: Contingent consideration 2018 (Dollars in thousands) Balance - December 31, 2017 $ 272,136 Additions (1) 396 Payment (64,372 ) Revaluations 34,618 Translation adjustment (119 ) Balance - July 1, 2018 $ 242,659 (1) The Company established a liability related to the estimated fair value of contingent consideration associated with the acquired assets from QT Vascular.

Shareholders' equity

Shareholders' equity	6 Months Ended
	Jul. 01, 2018
Equity [Abstract]
Shareholders' equity	Note 10 — Shareholders’ equity Basic earnings per share is computed by dividing net income by the weighted average number of common shares outstanding during the period. Diluted earnings per share is computed in the same manner except that the weighted average number of shares is increased to include dilutive securities. The following table provides a reconciliation of basic to diluted weighted average number of common shares outstanding: Three Months Ended Six Months Ended July 1, 2018 July 2, 2017 July 1, 2018 July 2, 2017 (Shares in thousands) Basic 45,581 44,996 45,455 44,945 Dilutive effect of share-based awards — 866 1,052 843 Dilutive effect of convertible notes and warrants — 956 264 928 Diluted 45,581 46,818 46,771 46,716 The weighted average number of shares that were antidilutive and therefore excluded from the calculation of earnings per share were 2.0 million (inclusive of 1.2 million potentially dilutive shares that were excluded because of the net loss for the three months ended July 1, 2018 ) and 0.7 million for the three and six months ended July 1, 2018 , respectively, and 0.7 million and 0.6 million for the three and six months ended July 2, 2017 , respectively. In connection with the issuance by the Company in 2010 of convertible notes that matured in August 2017, and as part of hedging arrangements between the Company and two institutional counterparties, the Company issued warrants to the counterparties, entitling them to purchase Company common stock. These transactions are described in greater detail in Note 11 to the consolidated financial statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2017. At July 1, 2018, warrants to purchase 197,274 shares at an exercise price of $74.65 per share remained outstanding. The remaining warrants expire ratably over a period ending on August 31, 2018. At July 1, 2018, the intrinsic value of the warrants (i.e. the excess of the aggregate market price of the underlying shares over the aggregate exercise price of the warrants) was $38.5 million . The following tables provide information relating to the changes in accumulated other comprehensive loss, net of tax, for the six months ended July 1, 2018 and July 2, 2017 : Cash Flow Hedges Pension and Other Postretirement Benefit Plans Foreign Currency Translation Adjustment Accumulated Other Comprehensive (Loss) Income (Dollars in thousands) Balance as of December 31, 2017 $ 340 $ (138,808 ) $ (126,623 ) $ (265,091 ) Other comprehensive income (loss) before reclassifications 1,103 188 (44,517 ) (43,226 ) Amounts reclassified from accumulated other comprehensive income (811 ) 2,708 — 1,897 Net current-period other comprehensive income (loss) 292 2,896 (44,517 ) (41,329 ) Balance as of July 1, 2018 $ 632 $ (135,912 ) $ (171,140 ) $ (306,420 ) Cash Flow Hedges Pension and Other Postretirement Benefit Plans Foreign Currency Translation Adjustment Accumulated Other Comprehensive (Loss) Income (Dollars in thousands) Balance at December 31, 2016 $ (2,424 ) $ (136,596 ) $ (299,697 ) $ (438,717 ) Other comprehensive (loss) before reclassifications 2,684 (669 ) 112,667 114,682 Amounts reclassified from accumulated other comprehensive loss 2,477 2,263 — 4,740 Net current-period other comprehensive income 5,161 1,594 112,667 119,422 Balance at July 2, 2017 $ 2,737 $ (135,002 ) $ (187,030 ) $ (319,295 ) The following table provides information relating to the location in the statements of operations and amount of reclassifications of losses/(gains) in accumulated other comprehensive (loss) income into expense/(income), net of tax, for the three and six months ended July 1, 2018 and July 2, 2017 : Three Months Ended Six Months Ended July 1, 2018 July 2, 2017 July 1, 2018 July 2, 2017 (Dollars in thousands) (Gains) losses on foreign exchange contracts: Cost of goods sold $ (118 ) $ 1,303 $ (951 ) $ 2,948 Total before tax (118 ) 1,303 (951 ) 2,948 Taxes (benefit) 27 (204 ) 140 (471 ) Net of tax $ (91 ) $ 1,099 $ (811 ) $ 2,477 Amortization of pension and other postretirement benefit items (1): Actuarial losses $ 1,734 $ 1,727 $ 3,480 $ 3,453 Prior-service costs 23 30 47 59 Total before tax 1,757 1,757 3,527 3,512 Tax benefit (408 ) (625 ) (819 ) (1,249 ) Net of tax $ 1,349 $ 1,132 $ 2,708 $ 2,263 Total reclassifications, net of tax $ 1,258 $ 2,231 $ 1,897 $ 4,740 (1) These accumulated other comprehensive (loss) income components are included in the computation of net benefit expense for pension and other postretirement benefit plans (see Note 12 for additional information).

Taxes on income from continuing

Taxes on income from continuing operations	6 Months Ended
	Jul. 01, 2018
Income Tax Disclosure [Abstract]
Taxes on income from continuing operations	Note 11 — Taxes on income from continuing operations Three Months Ended Six Months Ended July 1, 2018 July 2, 2017 July 1, 2018 July 2, 2017 Effective income tax rate 136.3% 13.4% 23.2% 7.4% The Tax Cuts and Jobs Act (the “TCJA”) was enacted on December 22, 2017. The legislation significantly changes U.S. tax law by, among other things, permanently reducing corporate income tax rates from a maximum of 35% to 21%, effective January 1, 2018; implementing a territorial tax system, by generally providing for, among other things, a dividends received deduction on the foreign source portion of dividends received from a foreign corporation if specified conditions are met; and imposing a one-time repatriation tax on undistributed post-1986 foreign subsidiary earnings and profits, which are deemed repatriated for purposes of the tax. In addition, the TCJA imposes two new U.S. tax base erosion provisions: (1) the global intangible low-taxed income ("GILTI") provisions and (2) the base erosion and anti-abuse tax ("BEAT") provisions, which are explained in more detail in Note 13 to the Company’s consolidated financial statements included in its Annual Report on Form 10-K for the year ended December 31, 2017. In accordance with the applicable provisions of SEC Staff Accounting Bulletin No. 118, the Company included in its consolidated financial statements as of December 31, 2017 provisional amounts reflecting the tax impact related to deemed repatriated earnings and the revaluation of deferred tax assets and liabilities. Once the Company's accounting for the income tax effects of the TCJA is complete, the amounts with respect to the income tax effects of the TCJA may differ from the provisional amounts, possibly materially, due to, among other things, additional analysis, changes in interpretations and assumptions the Company has made, additional regulatory guidance that may be issued, and actions the Company may take as a result of the TCJA. The effective income tax rate for the three and six months ended July 1, 2018 was 136.3% and 23.2% , respectively, and 13.4% and 7.4% for the three and six months ended July 2, 2017 , respectively. The effective income tax rate for the three and six months ended July 1, 2018 as compared to the prior year periods reflect non-deductible termination benefits and other costs incurred in connection with the 2018 Footprint realignment plan and a non-deductible contingent consideration expense recognized in connection with an increase in the fair value of the NeoTract contingent consideration liability. In addition, the effective tax rate for the three and six months ended July 1, 2018 includes the benefit of a lower U.S. corporate tax rate of 21.0% resulting from the enactment of the TCJA, partially offset by a tax cost associated with GILTI and other TCJA related changes. The effective tax rate for the six months ended July 2, 2017 reflects a tax benefit associated with costs incurred in connection with the Vascular Solutions acquisition.

Pension and other postretiremen

Pension and other postretirement benefits	6 Months Ended
	Jul. 01, 2018
Retirement Benefits [Abstract]
Pension and other postretirement benefits	Note 12 — Pension and other postretirement benefits The Company has a number of defined benefit pension and postretirement plans covering eligible U.S. and non-U.S. employees. As of July 1, 2018 , no further benefits are being accrued under the Company’s U.S. defined benefit pension plans and the Company’s other postretirement benefit plans, other than certain postretirement benefit plans covering employees subject to a collective bargaining agreement. Net pension and other postretirement benefits expense (income) consist of the following: Pension Other Postretirement Benefits Pension Other Postretirement Benefits July 1, 2018 July 2, 2017 July 1, 2018 July 2, 2017 July 1, 2018 July 2, 2017 July 1, 2018 July 2, 2017 (Dollars in thousands) Service cost $ 376 $ 720 $ 52 $ 75 $ 754 $ 1,437 $ 104 $ 149 Interest cost 3,718 3,789 378 379 7,439 7,574 756 757 Expected return on plan assets (7,415 ) (6,750 ) — — (14,836 ) (13,493 ) — — Net amortization and deferral 1,695 1,691 62 66 3,403 3,381 124 131 Net benefits expense (income) $ (1,626 ) $ (550 ) $ 492 $ 520 $ (3,240 ) $ (1,101 ) $ 984 $ 1,037

Commitments and contingent liab

Commitments and contingent liabilities	6 Months Ended
	Jul. 01, 2018
Commitments and Contingencies Disclosure [Abstract]
Commitments and contingent liabilities	Note 13 — Commitments and contingent liabilities Environmental: The Company is subject to contingencies as a result of environmental laws and regulations that in the future may require the Company to take further action to correct the effects on the environment of prior disposal practices or releases of chemical or petroleum substances by the Company or other parties. Much of this liability results from the U.S. Comprehensive Environmental Response, Compensation and Liability Act, often referred to as Superfund, the U.S. Resource Conservation and Recovery Act and similar state laws. These laws require the Company to undertake certain investigative and remedial activities at sites where the Company conducts or once conducted operations or at sites where Company-generated waste was disposed. Remediation activities vary substantially in duration and cost from site to site. These activities, and their associated costs, depend on the mix of unique site characteristics, evolving remediation technologies, the regulatory agencies involved and their enforcement policies, as well as the presence or absence of other potentially responsible parties. At July 1, 2018 , the Company has recorded $1.0 million and $5.7 million in accrued liabilities and other liabilities, respectively, relating to these matters. Considerable uncertainty exists with respect to these liabilities and, if adverse changes in circumstances occur, the potential liability may exceed the amount accrued as of July 1, 2018 . The time frame over which the accrued amounts may be paid out, based on past history, is estimated to be 15 - 20 years. Litigation: The Company is a party to various lawsuits and claims arising in the normal course of business. These lawsuits and claims include actions involving product liability, product warranty, commercial disputes, intellectual property, contract, employment, environmental and other matters. As of July 1, 2018 , the Company has recorded accrued liabilities of $1.7 million in connection with such contingencies, representing its best estimate of the cost within the range of estimated possible losses that will be incurred to resolve these matters. Based on information currently available, advice of counsel, established reserves and other resources, the Company does not believe that the outcome of any outstanding litigation and claims is likely to be, individually or in the aggregate, material to its business, financial condition, results of operations or liquidity. However, in the event of unexpected further developments, it is possible that the ultimate resolution of these matters, or other similar matters, if unfavorable, may be materially adverse to the Company’s business, financial condition, results of operations or liquidity. Legal costs such as outside counsel fees and expenses are charged to selling, general and administrative expenses in the period incurred. Tax audits and examinations: The Company and its subsidiaries are routinely subject to tax examinations by various tax authorities. As of July 1, 2018 , the most significant tax examinations in process are in Germany and Italy. The Company may establish reserves with respect to its uncertain tax positions, after which it adjusts the reserves to address developments with respect to its uncertain tax positions, including developments in these tax examinations. Accordingly, developments in tax audits and examinations, including resolution of uncertain tax positions, could result in increases or decreases to the Company’s recorded tax liabilities, which could impact the Company’s financial results. Other: The Company has various purchase commitments for materials, supplies and other items occurring in the ordinary conduct of its business. On average, such commitments are not at prices in excess of current market prices.

Segment information

Segment information	6 Months Ended
	Jul. 01, 2018
Segment Reporting [Abstract]
Segment information	Note 14 — Segment information Following the Company's acquisition of Vascular Solutions, the Company commenced an integration program under which it is combining the Vascular Solutions' business with some of its legacy businesses. As a result, effective during the fourth quarter 2017, the Company realigned its operating segments. The changes to the operating segments were also made to reflect the manner in which the Company’s chief operating decision maker assesses business performance and allocates resources. The Company now has the following seven reportable segments: Vascular North America, Interventional North America, Anesthesia North America, Surgical North America, Europe, Middle East and Africa ("EMEA"), Asia and Original Equipment and Development Services ("OEM"). In connection with the presentation of segment information, the Company will continue to present certain operating segments, which currently include the Interventional Urology North America, Respiratory North America and Latin America operating segments, in the “all other” category because they are not material for separate disclosure. All prior comparative periods presented have been restated to reflect these changes. The following tables present the Company’s segment results for the three and six months ended July 1, 2018 and July 2, 2017 : Three Months Ended Six Months Ended July 1, 2018 July 2, 2017 July 1, 2018 July 2, 2017 (Dollars in thousands) Vascular North America $ 80,062 $ 78,796 $ 163,110 $ 157,807 Interventional North America 64,956 58,337 125,152 98,283 Anesthesia North America 50,490 49,081 101,055 97,288 Surgical North America 40,708 44,716 81,385 90,660 EMEA 153,415 138,469 313,285 272,043 Asia 72,413 65,998 130,657 116,166 OEM 52,594 45,132 98,448 88,478 All other 95,228 48,084 184,004 95,769 Net revenues $ 609,866 $ 528,613 $ 1,197,096 $ 1,016,494 Three Months Ended Six Months Ended July 1, 2018 July 2, 2017 July 1, 2018 July 2, 2017 (Dollars in thousands) (Dollars in thousands) Vascular North America $ 24,636 $ 18,472 $ 49,298 $ 36,762 Interventional North America 16,510 8,815 30,630 780 Anesthesia North America 14,716 20,056 32,049 33,360 Surgical North America 17,055 17,287 31,803 33,667 EMEA 26,535 23,594 58,305 44,904 Asia 20,746 18,941 34,114 29,825 OEM 13,552 10,337 22,568 19,458 All other (25,602 ) 9,017 (37,575 ) 18,344 Total segment operating profit (1) 108,148 126,519 221,192 217,100 Unallocated expenses (2) (74,658 ) (16,317 ) (100,859 ) (46,079 ) Income from continuing operations before interest, loss on extinguishment of debt and taxes $ 33,490 $ 110,202 $ 120,333 $ 171,021 (1) Segment operating profit includes segment net revenues from external customers reduced by the segment's standard cost of goods sold, adjusted for fixed manufacturing cost absorption variances, selling, general and administrative expenses, research and development expenses and an allocation of corporate expenses. Corporate expenses are allocated among the segments in proportion to the respective amounts of one of several items (such as net revenues, numbers of employees, and amount of time spent), depending on the category of expense involved. (2) Unallocated expenses primarily include manufacturing variances other than fixed manufacturing cost absorption variances, restructuring charges and gain on sale of assets. The following table provides total net revenues by geographic region (based on the Company's selling location) for the three and six months ended July 1, 2018 and July 2, 2017 : Three Months Ended Six Months Ended July 1, 2018 July 2, 2017 July 1, 2018 July 2, 2017 (Dollars in thousands) United States $ 356,468 $ 310,124 $ 700,825 $ 596,438 Europe 168,879 144,393 340,200 285,415 Asia 60,488 53,901 110,043 96,905 All other 24,031 20,195 46,028 37,736 Net revenues $ 609,866 $ 528,613 $ 1,197,096 $ 1,016,494

Condensed consolidating guarant

Condensed consolidating guarantor financial information	6 Months Ended
	Jul. 01, 2018
Condensed Consolidated Guarantor Financial Information [Abstract]
Condensed consolidating guarantor financial information	Condensed consolidating guarantor financial information The Company’s $250 million principal amount of 5.25% Senior Notes due 2024 (the “2024 Notes”), $400 million principal amount of 4.875% Senior Notes due 2026 (the “2026 Notes”) and $500 million principal amount of 4.625% Senior Notes due 2027 (the “2027 Notes," and collectively with the 2024 Notes and the 2026 Notes, the "Senior Notes") are issued by Teleflex Incorporated (the “Parent Company”), and payment of the Parent Company's obligations under the Senior Notes are guaranteed, jointly and severally, by certain of the Parent Company’s subsidiaries (each, a “Guarantor Subsidiary” and collectively, the “Guarantor Subsidiaries”). The 2024 Notes, 2026 Notes and 2027 Notes are guaranteed by the same Guarantor Subsidiaries. The guarantees are full and unconditional, subject to certain customary release provisions. Each Guarantor Subsidiary is directly or indirectly 100% owned by the Parent Company. The Company’s condensed consolidating statements of income and comprehensive income for the three and six months ended July 1, 2018 and July 2, 2017 , condensed consolidating balance sheets as of July 1, 2018 and December 31, 2017 and condensed consolidating statements of cash flows for the six months ended July 1, 2018 and July 2, 2017 , provide consolidated information for: a. Parent Company, the issuer of the guaranteed obligations; b. Guarantor Subsidiaries, on a combined basis; c. Non-Guarantor Subsidiaries (i.e., those subsidiaries of the Parent Company that have not guaranteed payment of the Senior Notes), on a combined basis; and d. Parent Company and its subsidiaries on a consolidated basis. The same accounting policies as described in Note 1 to the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017 are used by the Parent Company and each of its subsidiaries in connection with the condensed consolidating financial information, except for the use of the equity method of accounting to reflect ownership interests in subsidiaries, which are eliminated upon consolidation. Consolidating entries and eliminations in the following condensed consolidated financial statements represent adjustments to (a) eliminate intercompany transactions between or among the Parent Company, the Guarantor Subsidiaries and the Non-Guarantor Subsidiaries, (b) eliminate the investments in subsidiaries and (c) record consolidating entries. During the first quarter 2018, a Guarantor Subsidiary merged with and into Parent; the transaction is reflected as of the beginning of the earliest period presented in the condensed consolidating financial statements. TELEFLEX INCORPORATED AND SUBSIDIARIES CONDENSED CONSOLIDATING STATEMENTS OF INCOME AND COMPREHENSIVE INCOME Three Months Ended July 1, 2018 Parent Guarantor Non-Guarantor Eliminations Condensed (Dollars in thousands) Net revenues $ — $ 391,304 $ 326,279 $ (107,717 ) $ 609,866 Cost of goods sold — 231,487 143,532 (109,931 ) 265,088 Gross profit — 159,817 182,747 2,214 344,778 Selling, general and administrative expenses 12,430 139,565 77,723 199 229,917 Research and development expenses 489 18,818 6,711 — 26,018 Restructuring and impairment charges — 2,545 52,808 — 55,353 (Loss) income from continuing operations before interest and taxes (12,919 ) (1,111 ) 45,505 2,015 33,490 Interest, net 24,788 1,078 600 — 26,466 (Loss) income from continuing operations before taxes (37,707 ) (2,189 ) 44,905 2,015 7,024 (Benefit) taxes on (loss) income from continuing operations (13,218 ) 7,486 15,245 63 9,576 Equity in net income of consolidated subsidiaries 21,937 24,457 342 (46,736 ) — (Loss) income from continuing operations (2,552 ) 14,782 30,002 (44,784 ) (2,552 ) Operating income from discontinued operations 94 — — — 94 Taxes on income from discontinued operations 38 — — — 38 Income from discontinued operations 56 — — — 56 Net (loss) income (2,496 ) 14,782 30,002 (44,784 ) (2,496 ) Other comprehensive loss (124,019 ) (114,917 ) (130,725 ) 245,642 (124,019 ) Comprehensive loss $ (126,515 ) $ (100,135 ) $ (100,723 ) $ 200,858 $ (126,515 ) Three Months Ended July 2, 2017 Parent Guarantor Non-Guarantor Eliminations Condensed Consolidated (Dollars in thousands) Net revenues $ — $ 338,620 $ 296,977 $ (106,984 ) $ 528,613 Cost of goods sold — 190,202 152,440 (104,313 ) 238,329 Gross profit — 148,418 144,537 (2,671 ) 290,284 Selling, general and administrative expenses 7,468 95,171 56,334 (39 ) 158,934 Research and development expenses 264 13,594 6,420 — 20,278 Restructuring charges — 1,335 (465 ) — 870 (Loss) income from continuing operations before interest, extinguishment of debt and taxes (7,732 ) 38,318 82,248 (2,632 ) 110,202 Interest, net 27,233 (8,581 ) 1,081 — 19,733 Loss on extinguishment of debt 11 — — — 11 (Loss) income from continuing operations before taxes (34,976 ) 46,899 81,167 (2,632 ) 90,458 (Benefit) taxes on (loss) income from continuing operations (14,378 ) 13,386 14,210 (1,123 ) 12,095 Equity in net income of consolidated subsidiaries 98,961 58,861 240 (158,062 ) — Income from continuing operations 78,363 92,374 67,197 (159,571 ) 78,363 Operating loss from discontinued operations (566 ) — — — (566 ) Tax benefit on loss from discontinued operations (206 ) — — — (206 ) Loss from discontinued operations (360 ) — — — (360 ) Net income 78,003 92,374 67,197 (159,571 ) 78,003 Other comprehensive income 69,822 68,127 69,374 (137,501 ) 69,822 Comprehensive income $ 147,825 $ 160,501 $ 136,571 $ (297,072 ) $ 147,825 Six Months Ended July 1, 2018 Parent Guarantor Non-Guarantor Eliminations Condensed (Dollars in thousands) Net revenues $ — $ 770,723 $ 646,288 $ (219,915 ) $ 1,197,096 Cost of goods sold — 449,091 285,540 (213,583 ) 521,048 Gross profit — 321,632 360,748 (6,332 ) 676,048 Selling, general and administrative expenses 21,611 270,479 153,494 (330 ) 445,254 Research and development expenses 716 38,186 13,143 — 52,045 Restructuring and impairment charges — 3,453 54,963 — 58,416 (Loss) income from continuing operations before interest and taxes (22,327 ) 9,514 139,148 (6,002 ) 120,333 Interest, net 46,929 4,009 1,198 — 52,136 (Loss) income from continuing operations before taxes (69,256 ) 5,505 137,950 (6,002 ) 68,197 (Benefit) taxes on (loss) income from continuing operations (26,410 ) 13,909 29,422 (1,103 ) 15,818 Equity in net income of consolidated subsidiaries 96,504 101,333 635 (198,472 ) — Income from continuing operations 53,658 92,929 109,163 (203,371 ) 52,379 Operating income from discontinued operations 50 — 1,279 — 1,329 Taxes on income from discontinued operations 20 — — — 20 Income from discontinued operations 30 — 1,279 — 1,309 Net income 53,688 92,929 110,442 (203,371 ) 53,688 Other comprehensive loss (41,329 ) (44,798 ) (43,498 ) 88,296 (41,329 ) Comprehensive income $ 12,359 $ 48,131 $ 66,944 $ (115,075 ) $ 12,359 Six Months Ended July 2, 2017 Parent Guarantor Non-Guarantor Eliminations Condensed (Dollars in thousands) Net revenues $ — $ 654,263 $ 573,292 $ (211,061 ) $ 1,016,494 Cost of goods sold — 382,203 296,336 (207,889 ) 470,650 Gross profit — 272,060 276,956 (3,172 ) 545,844 Selling, general and administrative expenses 27,987 189,214 105,178 524 322,903 Research and development expenses 499 24,780 12,826 — 38,105 Restructuring charges — 6,709 7,106 — 13,815 (Loss) income from continuing operations before interest, extinguishment of debt and taxes (28,486 ) 51,357 151,846 (3,696 ) 171,021 Interest, net 51,506 (16,143 ) 1,927 — 37,290 Loss on extinguishment of debt 5,593 — — — 5,593 (Loss) income from continuing operations before taxes (85,585 ) 67,500 149,919 (3,696 ) 128,138 (Benefit) taxes on (loss) income from continuing operations (35,711 ) 19,297 26,439 (599 ) 9,426 Equity in net income of consolidated subsidiaries 168,586 114,663 456 (283,705 ) — Income from continuing operations 118,712 162,866 123,936 (286,802 ) 118,712 Operating loss from discontinued operations (848 ) — — — (848 ) Tax benefit on loss from discontinued operations (309 ) — — — (309 ) Loss from discontinued operations (539 ) — — — (539 ) Net income 118,173 162,866 123,936 (286,802 ) 118,173 Other comprehensive income 119,422 117,531 123,275 (240,806 ) 119,422 Comprehensive income $ 237,595 $ 280,397 $ 247,211 $ (527,608 ) $ 237,595 TELEFLEX INCORPORATED AND SUBSIDIARIES CONDENSED CONSOLIDATING BALANCE SHEETS July 1, 2018 Parent Guarantor Non-Guarantor Eliminations Condensed (Dollars in thousands) ASSETS Current assets Cash and cash equivalents $ 50,786 $ 12,626 $ 282,892 $ — $ 346,304 Accounts receivable, net 2,328 49,185 302,614 4,992 359,119 Accounts receivable from consolidated subsidiaries 25,539 1,004,686 359,567 (1,389,792 ) — Inventories, net — 246,255 191,580 (32,407 ) 405,428 Prepaid expenses and other current assets 14,657 13,029 20,437 3,982 52,105 Prepaid taxes 11,811 — 7,273 — 19,084 Assets held for sale — 3,239 — — 3,239 Total current assets 105,121 1,329,020 1,164,363 (1,413,225 ) 1,185,279 Property, plant and equipment, net 2,887 233,105 174,987 — 410,979 Goodwill — 1,245,806 975,082 — 2,220,888 Intangibles assets, net — 1,312,928 993,276 — 2,306,204 Investments in consolidated subsidiaries 5,838,568 1,661,595 20,367 (7,520,530 ) — Deferred tax assets — — 4,670 (2,284 ) 2,386 Notes receivable and other amounts due from consolidated subsidiaries 2,255,108 2,313,458 — (4,568,566 ) — Other assets 30,547 5,880 13,158 — 49,585 Total assets $ 8,232,231 $ 8,101,792 $ 3,345,903 $ (13,504,605 ) $ 6,175,321 LIABILITIES AND EQUITY Current liabilities Current borrowings $ 36,875 $ — $ 50,000 $ — $ 86,875 Accounts payable 4,258 53,913 36,663 — 94,834 Accounts payable to consolidated subsidiaries 1,033,197 288,217 68,378 (1,389,792 ) — Accrued expenses 18,991 33,421 51,928 — 104,340 Current portion of contingent consideration — 110,454 — — 110,454 Payroll and benefit-related liabilities 15,958 34,341 39,370 — 89,669 Accrued interest 6,731 — 40 — 6,771 Income taxes payable — — 6,700 (1,103 ) 5,597 Other current liabilities 874 33,609 3,422 — 37,905 Total current liabilities 1,116,884 553,955 256,501 (1,390,895 ) 536,445 Long-term borrowings 2,145,468 — — — 2,145,468 Deferred tax liabilities 89,938 260,624 248,156 (2,284 ) 596,434 Pension and postretirement benefit liabilities 63,481 32,283 17,319 — 113,083 Noncurrent liability for uncertain tax positions 1,680 8,294 2,791 — 12,765 Notes payable and other amounts due to consolidated subsidiaries 2,240,361 2,125,535 202,670 (4,568,566 ) — Noncurrent contingent consideration — 121,116 11,089 — 132,205 Other liabilities 140,438 6,763 57,739 — 204,940 Total liabilities 5,798,250 3,108,570 796,265 (5,961,745 ) 3,741,340 Total shareholders' equity 2,433,981 4,993,222 2,549,638 (7,542,860 ) 2,433,981 Total liabilities and shareholders' equity $ 8,232,231 $ 8,101,792 $ 3,345,903 $ (13,504,605 ) $ 6,175,321 December 31, 2017 Parent Guarantor Non-Guarantor Eliminations Condensed (Dollars in thousands) ASSETS Current assets Cash and cash equivalents $ 37,803 $ 8,933 $ 286,822 $ — $ 333,558 Accounts receivable, net 2,414 57,818 280,980 4,663 345,875 Accounts receivable from consolidated subsidiaries 14,478 1,177,246 343,115 (1,534,839 ) — Inventories, net — 245,533 176,490 (26,279 ) 395,744 Prepaid expenses and other current assets 14,874 9,236 19,790 3,982 47,882 Prepaid taxes — — 5,748 — 5,748 Total current assets 69,569 1,498,766 1,112,945 (1,552,473 ) 1,128,807 Property, plant and equipment, net 2,088 213,663 167,248 — 382,999 Goodwill — 1,246,144 989,448 — 2,235,592 Intangibles assets, net — 1,355,275 1,028,473 — 2,383,748 Investments in consolidated subsidiaries 5,806,244 1,674,077 19,620 (7,499,941 ) — Deferred tax assets — — 6,071 (2,261 ) 3,810 Notes receivable and other amounts due from consolidated subsidiaries 2,452,101 2,231,832 — (4,683,933 ) — Other assets 31,173 6,397 8,966 — 46,536 Total assets $ 8,361,175 $ 8,226,154 $ 3,332,771 $ (13,738,608 ) $ 6,181,492 LIABILITIES AND EQUITY Current liabilities Current borrowings $ 36,625 $ — $ 50,000 $ — $ 86,625 Accounts payable 4,269 46,992 40,766 — 92,027 Accounts payable to consolidated subsidiaries 1,211,568 261,121 62,150 (1,534,839 ) — Accrued expenses 17,957 31,827 47,069 — 96,853 Current portion of contingent consideration — 74,224 — — 74,224 Payroll and benefit-related liabilities 21,145 44,009 42,261 — 107,415 Accrued interest 6,133 — 32 — 6,165 Income taxes payable 4,352 — 7,162 — 11,514 Other current liabilities 1,461 3,775 3,817 — 9,053 Total current liabilities 1,303,510 461,948 253,257 (1,534,839 ) 483,876 Long-term borrowings 2,162,927 — — — 2,162,927 Deferred tax liabilities 88,512 265,426 251,999 (2,261 ) 603,676 Pension and postretirement benefit liabilities 70,860 32,750 17,800 — 121,410 Noncurrent liability for uncertain tax positions 1,117 8,196 2,983 — 12,296 Notes payable and other amounts due to consolidated subsidiaries 2,155,146 2,320,611 208,176 (4,683,933 ) — Noncurrent contingent consideration — 186,923 10,989 — 197,912 Other liabilities 148,572 7,850 12,442 — 168,864 Total liabilities 5,930,644 3,283,704 757,646 (6,221,033 ) 3,750,961 Total shareholders' equity 2,430,531 4,942,450 2,575,125 (7,517,575 ) 2,430,531 Total liabilities and shareholders' equity $ 8,361,175 $ 8,226,154 $ 3,332,771 $ (13,738,608 ) $ 6,181,492 TELEFLEX INCORPORATED AND SUBSIDIARIES CONDENSED CONSOLIDATING STATEMENTS OF CASH FLOWS Six Months Ended July 1, 2018 Parent Guarantor Non-Guarantor Eliminations Condensed (Dollars in thousands) Net cash (used in) provided by operating activities from continuing operations $ (165,764 ) $ 253,365 $ 164,356 $ (70,373 ) $ 181,584 Cash flows from investing activities of continuing operations: Expenditures for property, plant and equipment (795 ) (16,602 ) (20,607 ) — (38,004 ) Proceeds from sale of investments 22,944 — — (22,944 ) — Payments for businesses and intangibles acquired, net of cash acquired — 1,404 (23,854 ) — (22,450 ) Net cash provided by (used in) investing activities from continuing operations 22,149 (15,198 ) (44,461 ) (22,944 ) (60,454 ) Cash flows from financing activities of continuing operations: Reduction in borrowings (18,500 ) — — — (18,500 ) Debt extinguishment, issuance and amendment fees (188 ) — — — (188 ) Net proceeds from share based compensation plans and the related tax impacts 9,800 — — — 9,800 Payments for contingent consideration — (62,574 ) — — (62,574 ) Dividends paid (30,938 ) — — — (30,938 ) Intercompany transactions 196,888 (171,900 ) (47,932 ) 22,944 — Intercompany dividends paid — — (70,373 ) 70,373 — Net cash provided by (used in) financing activities from continuing operations 157,062 (234,474 ) (118,305 ) 93,317 (102,400 ) Cash flows from discontinued operations: Net cash used in operating activities (464 ) — — — (464 ) Net cash used in discontinued operations (464 ) — — — (464 ) Effect of exchange rate changes on cash and cash equivalents — — (5,520 ) — (5,520 ) Net increase (decrease) in cash and cash equivalents 12,983 3,693 (3,930 ) — 12,746 Cash and cash equivalents at the beginning of the period 37,803 8,933 286,822 — 333,558 Cash and cash equivalents at the end of the period $ 50,786 $ 12,626 $ 282,892 $ — $ 346,304 Six Months Ended July 2, 2017 Parent Guarantor Non-Guarantor Eliminations Condensed (Dollars in thousands) Net cash (used in) provided by operating activities from continuing operations $ (121,726 ) $ 232,874 $ 148,460 $ (61,918 ) $ 197,690 Cash flows from investing activities of continuing operations: Expenditures for property, plant and equipment (173 ) (19,760 ) (16,900 ) — (36,833 ) Proceeds from sale of assets — — 6,332 — 6,332 Payments for businesses and intangibles acquired, net of cash acquired (975,524 ) — (17,935 ) — (993,459 ) Net cash used in investing activities from continuing operations (975,697 ) (19,760 ) (28,503 ) — (1,023,960 ) Cash flows from financing activities of continuing operations: Proceeds from new borrowings 1,194,500 — — — 1,194,500 Reduction in borrowings (228,273 ) — — — (228,273 ) Debt extinguishment, issuance and amendment fees (19,114 ) — — — (19,114 ) Net proceeds from share based compensation plans and the related tax impacts 1,305 — — — 1,305 Payments for contingent consideration — (153 ) — — (153 ) Dividends paid (30,590 ) — — — (30,590 ) Intercompany transactions 222,684 (203,029 ) (19,655 ) — — Intercompany dividends paid — — (61,918 ) 61,918 — Net cash provided by (used in) financing activities from continuing operations 1,140,512 (203,182 ) (81,573 ) 61,918 917,675 Cash flows from discontinued operations: Net cash used in operating activities (961 ) — — — (961 ) Net cash used in discontinued operations (961 ) — — — (961 ) Effect of exchange rate changes on cash and cash equivalents — — 41,981 — 41,981 Net increase in cash and cash equivalents 42,128 9,932 80,365 — 132,425 Cash and cash equivalents at the beginning of the period 14,571 1,031 528,187 — 543,789 Cash and cash equivalents at the end of the period $ 56,699 $ 10,963 $ 608,552 $ — $ 676,214

New accounting standards (Polic

New accounting standards (Policies)	6 Months Ended
	Jul. 01, 2018
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]
New accounting standards	New accounting standards In May 2014, the Financial Accounting Standards Board ("FASB"), in a joint effort with the International Accounting Standards Board ("IASB"), issued new accounting guidance to clarify the principles for recognizing revenue. This new guidance, as amended by additional guidance issued in 2015 and 2016, is encompassed in FASB Accounting Standards Codification Topic 606, Revenue from Contracts with Customers (“ASC 606”) and is designed to enhance the comparability of revenue recognition practices across entities, industries, jurisdictions and capital markets, and affects any entity that enters into contracts with customers or enters into contracts for the transfer of nonfinancial assets, unless those contracts are within the scope of other standards. The new guidance establishes principles for reporting information to users of financial statements about the nature, amount, timing, and uncertainty of revenue and cash flows arising from an entity's contracts with customers. The core principle of the new guidance is that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods and services. The Company adopted the new standard on January 1, 2018, applying the modified retrospective method to all of its contracts; as a result, the Company recognized the cumulative effect of adopting the guidance as a $1.2 million increase to the Company's opening balance of retained earnings on the adoption date. In addition, in connection with its adoption of the new guidance, the Company reclassified the reserve for product returns from a reduction of receivables to a liability. The reserve for returns and allowances was $4.2 million at July 1, 2018. The adoption of this guidance did not have a material impact on the Company's consolidated results of operations, cash flows and financial position. Additional information and disclosures required by this new standard are contained in Note 3. In February 2016, the FASB issued guidance that will change the requirements for accounting for leases. Under the new guidance, lessees (including lessees under both leases classified as finance leases, which are to be classified based on criteria similar to that applicable to capital leases under current guidance, and leases classified as operating leases) will recognize a right-to-use asset and a lease liability on the balance sheet, initially measured as the present value of lease payments under the lease. Under current guidance, operating leases are not recognized on the balance sheet. The standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted. The new standard must be adopted using a modified retrospective transition approach for leases with an option to elect a package of practical expedients. Further, companies can elect to apply the transition approach either for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements or those existing at, or entered into after, the adoption date. The Company is currently evaluating this guidance to determine its impact on the Company’s consolidated results of operations, cash flows and financial position. In October 2016, the FASB issued new guidance requiring companies to recognize the income tax effects of intra-entity sales and transfers of assets, other than inventory, in the income statement as income tax expense (or benefit) in the period in which the transfer occurs. Previously, recognition was prohibited until the assets were sold to an outside party or otherwise utilized. The Company adopted the new standard on January 1, 2018 using the modified retrospective method of adoption; as a result, the Company recognized the cumulative effect of adopting the guidance as a $1.8 million increase to the Company's opening balance of retained earnings on the adoption date. The adoption of this guidance did not have a material impact on the Company's consolidated results of operations, cash flows and financial position. In March 2017, the FASB issued guidance for employers that sponsor defined benefit pension or other postretirement benefit plans. The guidance requires that these employers disaggregate specified components of net periodic pension cost and net periodic postretirement benefit cost (collectively, "net benefit cost"). Specifically, the guidance generally requires employers to present in the income statement the service cost component of net benefit cost in the same line item or items as other compensation costs arising from services rendered by the pertinent employees during the period. The other components of net benefit cost are required to be presented in the income statement separately from the service cost component and outside a subtotal of income from operations. The Company adopted this guidance on January 1, 2018; the impact was not material to the consolidated financial statements. In August 2017, the FASB issued guidance with the objective of improving the financial reporting of hedging relationships to better portray the economic results of an entity's risk management activities in its financial statements. The new guidance provides for changes to current designation and measurement guidance for qualifying hedging relationships and to the method of presenting hedge results. In addition, the new guidance includes certain targeted improvements to ease the application of current guidance related to the assessment of hedge effectiveness. The new guidance is effective for reporting periods beginning after December 15, 2018. Early adoption is permitted. The Company is currently evaluating the impact of the adoption of this guidance on its consolidated results of operations and financial position. In February 2018, the FASB issued new guidance to address a narrow-scope financial reporting issue that arose as a consequence of the Tax Cuts and Jobs Act ("the TCJA"). Existing guidance requires that deferred tax liabilities and assets be adjusted for a change in tax laws or rates with the effect included in income from continuing operations in the reporting period that includes the enactment date. The guidance is applicable even in situations in which the related income tax effects of items in accumulated other comprehensive income were originally recognized in other comprehensive income (rather than in net income), such as amounts related to benefit plans and hedging activity. As a result, the tax effects of items within accumulated other comprehensive income (referred to as stranded tax effects) do not reflect the appropriate tax rate. The new guidance permits for a reclassification of these amounts to retained earnings, thereby eliminating the stranded tax effects. The new guidance also requires certain disclosures about the stranded tax effects. The guidance is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted for reporting periods for which financial statements have not yet been issued. The new guidance can be applied either in the period of adoption or retrospectively to each period (or periods) in which the effect of the change in the U.S. federal corporate income tax rate in the TCJA is recognized. The Company is currently evaluating the impact this guidance will have on its consolidated financial statements. From time to time, new accounting guidance is issued by the FASB or other standard setting bodies that is adopted by the Company as of the effective date or, in some cases where early adoption is permitted, in advance of the effective date. The Company has assessed the recently issued guidance that is not yet effective and, unless otherwise indicated above, believes the new guidance will not have a material impact on the its consolidated results of operations, cash flows or financial position.

Net revenues (Tables)

Net revenues (Tables)	6 Months Ended
	Jul. 01, 2018
Deferred Revenue Disclosure [Abstract]
Schedule of Revenue by Major Customers by Reporting Segments	The following table disaggregates revenue by global product category for the three and six months ended July 1, 2018 and July 2, 2017 . Three Months Ended Six Months Ended July 1, 2018 July 2, 2017 July 1, 2018 July 2, 2017 Revenue by global product category (1) (2) (Dollars in thousands) Vascular access $ 140,604 $ 133,323 $ 284,845 $ 263,345 Anesthesia 89,810 85,938 175,229 167,143 Interventional 77,179 68,425 148,858 112,391 Surgical 90,489 90,740 176,139 178,044 Interventional urology 47,674 — 89,974 — OEM 52,594 45,132 98,448 88,478 Other (3) 111,516 105,055 223,603 207,093 Net revenues $ 609,866 $ 528,613 $ 1,197,096 $ 1,016,494 (1) The product categories listed above are presented on a global basis; in contrast, the Company’s North American reportable segments generally are defined largely based on the particular products sold by the segments, and its non-North American reportable segments are defined exclusively based on the geographic location of segment operations (with the exception of the Original Equipment and Development Services ("OEM") reportable segment, which operates globally). The Company’s EMEA and Asia reportable segments, as well as its Latin America operating segment, include net revenues from each of the product categories listed above. (2) The methodology used to determine the product revenues included within certain of the product categories listed in the table above differs from the methodology used to recognize revenues in our reportable segments, including the similarly named North American reportable segments. The differences are due to the fact that segment classification generally is determined based on the call point within the customer's organization from which the purchase order resulting in the sales originated, while the classification of products within the product categories listed in the table above includes all sales of products within the listed product category, regardless of the call point within the customer's organization from which the sales originated. (3) Other revenues in the table above comprise the Company’s respiratory, urology and cardiac product categories.

Acquisitions (Tables)

Acquisitions (Tables)	6 Months Ended
	Jul. 01, 2018
Business Combinations [Abstract]
Business Acquisition, Pro Forma Information	The following unaudited pro forma combined financial information for the three and six months ended July 2, 2017 gives effect to the Vascular Solutions and NeoTract acquisitions as if they had occurred on January 1, 2016. The pro forma information is presented for informational purposes only and is not necessarily indicative of the results of operations that actually would have occurred under the ownership and management of the Company. Three Months Ended Six Months Ended July 2, 2017 July 2, 2017 (Dollars and shares in thousands, except per share) Net revenue $ 558,836 $ 1,092,154 Net income $ 66,726 $ 103,833 Basic earnings per common share: Net income $ 1.48 $ 2.31 Diluted earnings per common share: Net income $ 1.43 $ 2.22 Weighted average common shares outstanding: Basic 44,996 44,945 Diluted 46,818 46,716

Restructuring charges and imp27

Restructuring charges and impairment charges (Tables)	6 Months Ended
	Jul. 01, 2018
Restructuring and Related Activities [Abstract]
Restructuring and Other Impairment Charges	The following tables provide information regarding restructuring and impairment charges recognized by the Company for the three and six months ended July 1, 2018 and July 2, 2017 : Three Months Ended July 1, 2018 Termination benefits Other costs (2) Total (Dollars in thousands) 2018 Footprint realignment plan $ 52,345 $ 129 $ 52,474 Other restructuring programs (1) 574 440 1,014 Restructuring charges $ 52,919 $ 569 $ 53,488 Long-lived asset impairment charge — 1,865 1,865 Restructuring and impairment charges $ 52,919 $ 2,434 $ 55,353 Three Months Ended July 2, 2017 Termination benefits Other costs (2) Total (Dollars in thousands) Restructuring charges (3) $ 612 $ 258 $ 870 Six Months Ended July 1, 2018 Termination benefits Other costs (2) Total (Dollars in thousands) 2018 Footprint realignment plan $ 52,345 $ 129 $ 52,474 2016 Footprint realignment plan 2,199 291 2,490 Other restructuring programs (4) 1,032 555 1,587 Restructuring charges $ 55,576 $ 975 $ 56,551 Long-lived asset impairment charge — 1,865 1,865 Restructuring and impairment charges $ 55,576 $ 2,840 $ 58,416 Six Months Ended July 2, 2017 Termination benefits Other costs (2) Total (Dollars in thousands) Vascular Solutions integration program $ 4,853 $ 34 $ 4,887 2017 EMEA restructuring program 6,536 — 6,536 2016 Footprint realignment plan 825 76 901 Other restructuring programs (5) 1,147 344 1,491 Restructuring charges $ 13,361 $ 454 $ 13,815 (1) Other restructuring programs include the 2016 and 2014 Footprint realignment plans, the Vascular Solutions integration program and the 2017 EMEA restructuring program as well as the other 2016 restructuring programs. (2) Other costs include facility closure, contract termination, and other exit costs. (3) Restructuring charges include charges related to the Vascular Solutions integration program, 2017 EMEA restructuring program, the 2016 and 2014 footprint realignment plans, the 2017 Pyng integration program and the 2016 Other Restructuring programs. The Company committed to the 2017 Pyng integration program, which relates to the integration of Pyng Medical Corp. (“Pyng”) into the Company, during the second quarter of 2017, following the Company’s acquisition of Pyng in April 2017. (4) Other restructuring programs include the 2014 Footprint realignment plan, Vascular Solutions integration program, the 2017 EMEA restructuring program and the other 2016 restructuring programs. (5) Other restructuring programs include the 2014 Footprint realignment plan, the 2017 Pyng integration program and the 2016 Other Restructuring programs. Restructuring charges by reportable operating segment, and by all other operating segments in the aggregate, for the three and six months ended July 1, 2018 and July 2, 2017 are set forth in the following table: Three Months Ended Six Months Ended July 1, 2018 July 2, 2017 July 1, 2018 July 2, 2017 (Dollars in thousands) Vascular North America $ 202 $ 353 $ 523 $ 1,081 Interventional North America 362 191 907 4,406 Anesthesia North America 91 564 125 811 EMEA 52,539 (412 ) 52,790 7,115 All other 294 174 2,206 402 Restructuring charges $ 53,488 $ 870 $ 56,551 $ 13,815
Summary Of Current Cost Estimates By Major Type Of Cost Table	The following table provides a summary of the Company’s cost estimates by major type of expense associated with the 2018 Footprint realignment plan: Type of expense Total estimated amount expected to be incurred Termination benefits $60 million to $70 million Other exit costs (1) $2 million to $4 million Restructuring charges $62 million to $74 million Restructuring related charges (2) $40 million to $59 million Total restructuring and restructuring related charges $102 million to $133 million (1) Includes contract termination, facility closure, employee relocation, equipment relocation and outplacement costs. (2) Consists of pre-tax charges related to accelerated depreciation and other costs directly related to the plan, primarily project management costs and costs to transfer manufacturing operations to the new location, as well as a charge associated with the Company’s exit from the facilities that is expected to be imposed by the taxing authority in the affected jurisdiction. Excluding this tax charge, substantially all of the charges are expected to be recognized within costs of goods sold.

Inventories, net (Tables)

Inventories, net (Tables)	6 Months Ended
	Jul. 01, 2018
Inventory Disclosure [Abstract]
Inventories, net	Inventories as of July 1, 2018 and December 31, 2017 consisted of the following: July 1, 2018 December 31, 2017 (Dollars in thousands) Raw materials $ 103,005 $ 98,451 Work-in-process 63,386 62,381 Finished goods 239,037 234,912 Inventories, net $ 405,428 $ 395,744

Goodwill and other intangible29

Goodwill and other intangible assets, net (Tables)	6 Months Ended
	Jul. 01, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Goodwill	The following table provides information relating to changes in the carrying amount of goodwill by reportable operating segment, and by all other operating segments in the aggregate, for the six months ended July 1, 2018 : Vascular Interventional North America Anesthesia Surgical EMEA Asia OEM All Total (Dollars in thousands) December 31, 2017 $ 264,869 $ 433,049 $ 157,289 $ 250,912 $ 494,548 $ 209,200 $ 4,883 $ 420,842 $ 2,235,592 Goodwill related to acquisitions — 422 — — 9 3 — 145 579 Currency translation adjustment — (1,938 ) (395 ) — (9,836 ) (2,352 ) — (762 ) (15,283 ) July 1, 2018 $ 264,869 $ 431,533 $ 156,894 $ 250,912 $ 484,721 $ 206,851 $ 4,883 $ 420,225 $ 2,220,888
Schedule of Finite-Lived Intangible Assets	The Company's gross carrying amount of, and accumulated amortization relating to, intangible assets as of July 1, 2018 and December 31, 2017 were as follows: Gross Carrying Amount Accumulated Amortization July 1, 2018 December 31, 2017 July 1, 2018 December 31, 2017 (Dollars in thousands) Customer relationships $ 1,016,254 $ 1,023,837 $ (302,216 ) $ (281,263 ) In-process research and development 29,763 34,672 — — Intellectual property 1,295,555 1,287,487 (296,217 ) (258,580 ) Distribution rights 23,570 23,697 (17,417 ) (16,996 ) Trade names 568,227 571,510 (29,244 ) (22,069 ) Non-compete agreements 23,507 23,429 (5,578 ) (1,976 ) $ 2,956,876 $ 2,964,632 $ (650,672 ) $ (580,884 )

Financial instruments (Tables)

Financial instruments (Tables)	6 Months Ended
	Jul. 01, 2018
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Fair Values of Derivative Instruments Designated as Hedging Instruments	The following table presents the locations in the condensed consolidated balance sheet and fair value of derivative financial instruments as of July 1, 2018 and December 31, 2017 : July 1, 2018 December 31, 2017 Fair Value (Dollars in thousands) Asset derivatives: Designated foreign currency forward contracts $ 1,513 $ 914 Non-designated foreign currency forward contracts 441 307 Prepaid expenses and other current assets $ 1,954 $ 1,221 Total asset derivatives $ 1,954 $ 1,221 Liability derivatives: Designated foreign currency forward contracts $ 759 $ 1,373 Non-designated foreign currency forward contracts 102 53 Other current liabilities $ 861 $ 1,426 Total liability derivatives $ 861 $ 1,426
Aggregate Accounts Receivable, Net of Allowance for Doubtful Accounts	The following table provides information regarding the Company's allowance for doubtful accounts, the aggregate net current and long-term trade accounts receivable related to customers in Greece, Italy, Spain and Portugal and the percentage of the Company’s total net current and long-term trade accounts receivable represented by these customers' trade accounts receivable at July 1, 2018 and December 31, 2017 : July 1, 2018 December 31, 2017 (Dollars in thousands) Allowance for doubtful accounts (1) $ 9,525 $ 10,255 Current and long-term trade accounts receivable, net in Greece, Italy, Spain and Portugal (2) $ 52,569 $ 49,054 Percentage of total net current and long-term trade accounts receivable - Greece, Italy, Spain and Portugal 15.0 % 14.6 % (1) The current portion of the allowance for doubtful accounts was $3.6 million and $3.5 million as of July 1, 2018 and December 31, 2017 , respectively, and was recognized in accounts receivable, net. (2) The long-term portion of trade accounts receivable, net from customers in Greece, Italy, Spain and Portugal at July 1, 2018 and December 31, 2017 was $3.5 million and $3.3 million , respectively.

Fair value measurement (Tables)

Fair value measurement (Tables)	6 Months Ended
	Jul. 01, 2018
Fair Value Disclosures [Abstract]
Financial Assets and Liabilities Carried at Fair Value Measured on Recurring Basis	The following tables provide information regarding the Company's financial assets and liabilities that are measured at fair value on a recurring basis as of July 1, 2018 and December 31, 2017 : Total carrying Quoted prices in active Significant other Significant (Dollars in thousands) Investments in marketable securities $ 9,272 $ 9,272 $ — $ — Derivative assets 1,954 — 1,954 — Derivative liabilities 861 — 861 — Contingent consideration liabilities 242,659 — — 242,659 Total carrying Quoted prices in active Significant other Significant (Dollars in thousands) Investments in marketable securities $ 9,045 $ 9,045 $ — $ — Derivative assets 1,221 — 1,221 — Derivative liabilities 1,426 — 1,426 — Contingent consideration liabilities 272,136 — — 272,136
Reconciliation of Changes in Level 3 Financial Liabilities Measured at Fair Value on Recurring Basis	The following table provides information regarding changes, during the six months ended July 1, 2018 , in Level 3 financial liabilities related to contingent consideration: Contingent consideration 2018 (Dollars in thousands) Balance - December 31, 2017 $ 272,136 Additions (1) 396 Payment (64,372 ) Revaluations 34,618 Translation adjustment (119 ) Balance - July 1, 2018 $ 242,659 (1) The Company established a liability related to the estimated fair value of contingent consideration associated with the acquired assets from QT Vascular.
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]	The table below provides additional information regarding the valuation technique and inputs used in determining the fair value of contingent consideration recognized in connection with the NeoTract acquisition. Valuation Technique Unobservable Input Range Contingent consideration Monte Carlo simulation Revenue volatility 22.3 % Risk free rate Cost of debt structure Projected year of payment 2018 - 2021

Shareholders' equity (Tables)

Shareholders' equity (Tables)	6 Months Ended
	Jul. 01, 2018
Equity [Abstract]
Reconciliation of Basic to Diluted Weighted Average Common Shares Outstanding	The following table provides a reconciliation of basic to diluted weighted average number of common shares outstanding: Three Months Ended Six Months Ended July 1, 2018 July 2, 2017 July 1, 2018 July 2, 2017 (Shares in thousands) Basic 45,581 44,996 45,455 44,945 Dilutive effect of share-based awards — 866 1,052 843 Dilutive effect of convertible notes and warrants — 956 264 928 Diluted 45,581 46,818 46,771 46,716
Change in Accumulated Other Comprehensive Income (Loss)	The following tables provide information relating to the changes in accumulated other comprehensive loss, net of tax, for the six months ended July 1, 2018 and July 2, 2017 : Cash Flow Hedges Pension and Other Postretirement Benefit Plans Foreign Currency Translation Adjustment Accumulated Other Comprehensive (Loss) Income (Dollars in thousands) Balance as of December 31, 2017 $ 340 $ (138,808 ) $ (126,623 ) $ (265,091 ) Other comprehensive income (loss) before reclassifications 1,103 188 (44,517 ) (43,226 ) Amounts reclassified from accumulated other comprehensive income (811 ) 2,708 — 1,897 Net current-period other comprehensive income (loss) 292 2,896 (44,517 ) (41,329 ) Balance as of July 1, 2018 $ 632 $ (135,912 ) $ (171,140 ) $ (306,420 ) Cash Flow Hedges Pension and Other Postretirement Benefit Plans Foreign Currency Translation Adjustment Accumulated Other Comprehensive (Loss) Income (Dollars in thousands) Balance at December 31, 2016 $ (2,424 ) $ (136,596 ) $ (299,697 ) $ (438,717 ) Other comprehensive (loss) before reclassifications 2,684 (669 ) 112,667 114,682 Amounts reclassified from accumulated other comprehensive loss 2,477 2,263 — 4,740 Net current-period other comprehensive income 5,161 1,594 112,667 119,422 Balance at July 2, 2017 $ 2,737 $ (135,002 ) $ (187,030 ) $ (319,295 )
Reclassification of Gain/Losses into Income/Expense, Net of Tax	The following table provides information relating to the location in the statements of operations and amount of reclassifications of losses/(gains) in accumulated other comprehensive (loss) income into expense/(income), net of tax, for the three and six months ended July 1, 2018 and July 2, 2017 : Three Months Ended Six Months Ended July 1, 2018 July 2, 2017 July 1, 2018 July 2, 2017 (Dollars in thousands) (Gains) losses on foreign exchange contracts: Cost of goods sold $ (118 ) $ 1,303 $ (951 ) $ 2,948 Total before tax (118 ) 1,303 (951 ) 2,948 Taxes (benefit) 27 (204 ) 140 (471 ) Net of tax $ (91 ) $ 1,099 $ (811 ) $ 2,477 Amortization of pension and other postretirement benefit items (1): Actuarial losses $ 1,734 $ 1,727 $ 3,480 $ 3,453 Prior-service costs 23 30 47 59 Total before tax 1,757 1,757 3,527 3,512 Tax benefit (408 ) (625 ) (819 ) (1,249 ) Net of tax $ 1,349 $ 1,132 $ 2,708 $ 2,263 Total reclassifications, net of tax $ 1,258 $ 2,231 $ 1,897 $ 4,740 (1) These accumulated other comprehensive (loss) income components are included in the computation of net benefit expense for pension and other postretirement benefit plans (see Note 12 for additional information).

Taxes on income from continui33

Taxes on income from continuing operations (Tables)	6 Months Ended
	Jul. 01, 2018
Income Tax Disclosure [Abstract]
Effective Income Tax Rate	Three Months Ended Six Months Ended July 1, 2018 July 2, 2017 July 1, 2018 July 2, 2017 Effective income tax rate 136.3% 13.4% 23.2% 7.4%

Pension and other postretirem34

Pension and other postretirement benefits (Tables)	6 Months Ended
	Jul. 01, 2018
Retirement Benefits [Abstract]
Schedule of Net Benefit Cost of Pension and Postretirement Benefit Plans	Net pension and other postretirement benefits expense (income) consist of the following: Pension Other Postretirement Benefits Pension Other Postretirement Benefits July 1, 2018 July 2, 2017 July 1, 2018 July 2, 2017 July 1, 2018 July 2, 2017 July 1, 2018 July 2, 2017 (Dollars in thousands) Service cost $ 376 $ 720 $ 52 $ 75 $ 754 $ 1,437 $ 104 $ 149 Interest cost 3,718 3,789 378 379 7,439 7,574 756 757 Expected return on plan assets (7,415 ) (6,750 ) — — (14,836 ) (13,493 ) — — Net amortization and deferral 1,695 1,691 62 66 3,403 3,381 124 131 Net benefits expense (income) $ (1,626 ) $ (550 ) $ 492 $ 520 $ (3,240 ) $ (1,101 ) $ 984 $ 1,037

Segment information (Tables)

Segment information (Tables)	6 Months Ended
	Jul. 01, 2018
Segment Reporting [Abstract]
Segment Results	The following tables present the Company’s segment results for the three and six months ended July 1, 2018 and July 2, 2017 : Three Months Ended Six Months Ended July 1, 2018 July 2, 2017 July 1, 2018 July 2, 2017 (Dollars in thousands) Vascular North America $ 80,062 $ 78,796 $ 163,110 $ 157,807 Interventional North America 64,956 58,337 125,152 98,283 Anesthesia North America 50,490 49,081 101,055 97,288 Surgical North America 40,708 44,716 81,385 90,660 EMEA 153,415 138,469 313,285 272,043 Asia 72,413 65,998 130,657 116,166 OEM 52,594 45,132 98,448 88,478 All other 95,228 48,084 184,004 95,769 Net revenues $ 609,866 $ 528,613 $ 1,197,096 $ 1,016,494 Three Months Ended Six Months Ended July 1, 2018 July 2, 2017 July 1, 2018 July 2, 2017 (Dollars in thousands) (Dollars in thousands) Vascular North America $ 24,636 $ 18,472 $ 49,298 $ 36,762 Interventional North America 16,510 8,815 30,630 780 Anesthesia North America 14,716 20,056 32,049 33,360 Surgical North America 17,055 17,287 31,803 33,667 EMEA 26,535 23,594 58,305 44,904 Asia 20,746 18,941 34,114 29,825 OEM 13,552 10,337 22,568 19,458 All other (25,602 ) 9,017 (37,575 ) 18,344 Total segment operating profit (1) 108,148 126,519 221,192 217,100 Unallocated expenses (2) (74,658 ) (16,317 ) (100,859 ) (46,079 ) Income from continuing operations before interest, loss on extinguishment of debt and taxes $ 33,490 $ 110,202 $ 120,333 $ 171,021 (1) Segment operating profit includes segment net revenues from external customers reduced by the segment's standard cost of goods sold, adjusted for fixed manufacturing cost absorption variances, selling, general and administrative expenses, research and development expenses and an allocation of corporate expenses. Corporate expenses are allocated among the segments in proportion to the respective amounts of one of several items (such as net revenues, numbers of employees, and amount of time spent), depending on the category of expense involved. (2) Unallocated expenses primarily include manufacturing variances other than fixed manufacturing cost absorption variances, restructuring charges and gain on sale of assets.
Schedule Of Revenues By Geographic Region Table	The following table provides total net revenues by geographic region (based on the Company's selling location) for the three and six months ended July 1, 2018 and July 2, 2017 : Three Months Ended Six Months Ended July 1, 2018 July 2, 2017 July 1, 2018 July 2, 2017 (Dollars in thousands) United States $ 356,468 $ 310,124 $ 700,825 $ 596,438 Europe 168,879 144,393 340,200 285,415 Asia 60,488 53,901 110,043 96,905 All other 24,031 20,195 46,028 37,736 Net revenues $ 609,866 $ 528,613 $ 1,197,096 $ 1,016,494

Condensed consolidating guara36

Condensed consolidating guarantor financial information (Tables)	6 Months Ended
	Jul. 01, 2018
Condensed Consolidated Guarantor Financial Information [Abstract]
Condensed Consolidated Statements of Income (Loss) and Comprehensive Income (Loss)	TELEFLEX INCORPORATED AND SUBSIDIARIES CONDENSED CONSOLIDATING STATEMENTS OF INCOME AND COMPREHENSIVE INCOME Three Months Ended July 1, 2018 Parent Guarantor Non-Guarantor Eliminations Condensed (Dollars in thousands) Net revenues $ — $ 391,304 $ 326,279 $ (107,717 ) $ 609,866 Cost of goods sold — 231,487 143,532 (109,931 ) 265,088 Gross profit — 159,817 182,747 2,214 344,778 Selling, general and administrative expenses 12,430 139,565 77,723 199 229,917 Research and development expenses 489 18,818 6,711 — 26,018 Restructuring and impairment charges — 2,545 52,808 — 55,353 (Loss) income from continuing operations before interest and taxes (12,919 ) (1,111 ) 45,505 2,015 33,490 Interest, net 24,788 1,078 600 — 26,466 (Loss) income from continuing operations before taxes (37,707 ) (2,189 ) 44,905 2,015 7,024 (Benefit) taxes on (loss) income from continuing operations (13,218 ) 7,486 15,245 63 9,576 Equity in net income of consolidated subsidiaries 21,937 24,457 342 (46,736 ) — (Loss) income from continuing operations (2,552 ) 14,782 30,002 (44,784 ) (2,552 ) Operating income from discontinued operations 94 — — — 94 Taxes on income from discontinued operations 38 — — — 38 Income from discontinued operations 56 — — — 56 Net (loss) income (2,496 ) 14,782 30,002 (44,784 ) (2,496 ) Other comprehensive loss (124,019 ) (114,917 ) (130,725 ) 245,642 (124,019 ) Comprehensive loss $ (126,515 ) $ (100,135 ) $ (100,723 ) $ 200,858 $ (126,515 ) Three Months Ended July 2, 2017 Parent Guarantor Non-Guarantor Eliminations Condensed Consolidated (Dollars in thousands) Net revenues $ — $ 338,620 $ 296,977 $ (106,984 ) $ 528,613 Cost of goods sold — 190,202 152,440 (104,313 ) 238,329 Gross profit — 148,418 144,537 (2,671 ) 290,284 Selling, general and administrative expenses 7,468 95,171 56,334 (39 ) 158,934 Research and development expenses 264 13,594 6,420 — 20,278 Restructuring charges — 1,335 (465 ) — 870 (Loss) income from continuing operations before interest, extinguishment of debt and taxes (7,732 ) 38,318 82,248 (2,632 ) 110,202 Interest, net 27,233 (8,581 ) 1,081 — 19,733 Loss on extinguishment of debt 11 — — — 11 (Loss) income from continuing operations before taxes (34,976 ) 46,899 81,167 (2,632 ) 90,458 (Benefit) taxes on (loss) income from continuing operations (14,378 ) 13,386 14,210 (1,123 ) 12,095 Equity in net income of consolidated subsidiaries 98,961 58,861 240 (158,062 ) — Income from continuing operations 78,363 92,374 67,197 (159,571 ) 78,363 Operating loss from discontinued operations (566 ) — — — (566 ) Tax benefit on loss from discontinued operations (206 ) — — — (206 ) Loss from discontinued operations (360 ) — — — (360 ) Net income 78,003 92,374 67,197 (159,571 ) 78,003 Other comprehensive income 69,822 68,127 69,374 (137,501 ) 69,822 Comprehensive income $ 147,825 $ 160,501 $ 136,571 $ (297,072 ) $ 147,825 Six Months Ended July 1, 2018 Parent Guarantor Non-Guarantor Eliminations Condensed (Dollars in thousands) Net revenues $ — $ 770,723 $ 646,288 $ (219,915 ) $ 1,197,096 Cost of goods sold — 449,091 285,540 (213,583 ) 521,048 Gross profit — 321,632 360,748 (6,332 ) 676,048 Selling, general and administrative expenses 21,611 270,479 153,494 (330 ) 445,254 Research and development expenses 716 38,186 13,143 — 52,045 Restructuring and impairment charges — 3,453 54,963 — 58,416 (Loss) income from continuing operations before interest and taxes (22,327 ) 9,514 139,148 (6,002 ) 120,333 Interest, net 46,929 4,009 1,198 — 52,136 (Loss) income from continuing operations before taxes (69,256 ) 5,505 137,950 (6,002 ) 68,197 (Benefit) taxes on (loss) income from continuing operations (26,410 ) 13,909 29,422 (1,103 ) 15,818 Equity in net income of consolidated subsidiaries 96,504 101,333 635 (198,472 ) — Income from continuing operations 53,658 92,929 109,163 (203,371 ) 52,379 Operating income from discontinued operations 50 — 1,279 — 1,329 Taxes on income from discontinued operations 20 — — — 20 Income from discontinued operations 30 — 1,279 — 1,309 Net income 53,688 92,929 110,442 (203,371 ) 53,688 Other comprehensive loss (41,329 ) (44,798 ) (43,498 ) 88,296 (41,329 ) Comprehensive income $ 12,359 $ 48,131 $ 66,944 $ (115,075 ) $ 12,359 Six Months Ended July 2, 2017 Parent Guarantor Non-Guarantor Eliminations Condensed (Dollars in thousands) Net revenues $ — $ 654,263 $ 573,292 $ (211,061 ) $ 1,016,494 Cost of goods sold — 382,203 296,336 (207,889 ) 470,650 Gross profit — 272,060 276,956 (3,172 ) 545,844 Selling, general and administrative expenses 27,987 189,214 105,178 524 322,903 Research and development expenses 499 24,780 12,826 — 38,105 Restructuring charges — 6,709 7,106 — 13,815 (Loss) income from continuing operations before interest, extinguishment of debt and taxes (28,486 ) 51,357 151,846 (3,696 ) 171,021 Interest, net 51,506 (16,143 ) 1,927 — 37,290 Loss on extinguishment of debt 5,593 — — — 5,593 (Loss) income from continuing operations before taxes (85,585 ) 67,500 149,919 (3,696 ) 128,138 (Benefit) taxes on (loss) income from continuing operations (35,711 ) 19,297 26,439 (599 ) 9,426 Equity in net income of consolidated subsidiaries 168,586 114,663 456 (283,705 ) — Income from continuing operations 118,712 162,866 123,936 (286,802 ) 118,712 Operating loss from discontinued operations (848 ) — — — (848 ) Tax benefit on loss from discontinued operations (309 ) — — — (309 ) Loss from discontinued operations (539 ) — — — (539 ) Net income 118,173 162,866 123,936 (286,802 ) 118,173 Other comprehensive income 119,422 117,531 123,275 (240,806 ) 119,422 Comprehensive income $ 237,595 $ 280,397 $ 247,211 $ (527,608 ) $ 237,595
Condensed Consolidating Balance Sheets	TELEFLEX INCORPORATED AND SUBSIDIARIES CONDENSED CONSOLIDATING BALANCE SHEETS July 1, 2018 Parent Guarantor Non-Guarantor Eliminations Condensed (Dollars in thousands) ASSETS Current assets Cash and cash equivalents $ 50,786 $ 12,626 $ 282,892 $ — $ 346,304 Accounts receivable, net 2,328 49,185 302,614 4,992 359,119 Accounts receivable from consolidated subsidiaries 25,539 1,004,686 359,567 (1,389,792 ) — Inventories, net — 246,255 191,580 (32,407 ) 405,428 Prepaid expenses and other current assets 14,657 13,029 20,437 3,982 52,105 Prepaid taxes 11,811 — 7,273 — 19,084 Assets held for sale — 3,239 — — 3,239 Total current assets 105,121 1,329,020 1,164,363 (1,413,225 ) 1,185,279 Property, plant and equipment, net 2,887 233,105 174,987 — 410,979 Goodwill — 1,245,806 975,082 — 2,220,888 Intangibles assets, net — 1,312,928 993,276 — 2,306,204 Investments in consolidated subsidiaries 5,838,568 1,661,595 20,367 (7,520,530 ) — Deferred tax assets — — 4,670 (2,284 ) 2,386 Notes receivable and other amounts due from consolidated subsidiaries 2,255,108 2,313,458 — (4,568,566 ) — Other assets 30,547 5,880 13,158 — 49,585 Total assets $ 8,232,231 $ 8,101,792 $ 3,345,903 $ (13,504,605 ) $ 6,175,321 LIABILITIES AND EQUITY Current liabilities Current borrowings $ 36,875 $ — $ 50,000 $ — $ 86,875 Accounts payable 4,258 53,913 36,663 — 94,834 Accounts payable to consolidated subsidiaries 1,033,197 288,217 68,378 (1,389,792 ) — Accrued expenses 18,991 33,421 51,928 — 104,340 Current portion of contingent consideration — 110,454 — — 110,454 Payroll and benefit-related liabilities 15,958 34,341 39,370 — 89,669 Accrued interest 6,731 — 40 — 6,771 Income taxes payable — — 6,700 (1,103 ) 5,597 Other current liabilities 874 33,609 3,422 — 37,905 Total current liabilities 1,116,884 553,955 256,501 (1,390,895 ) 536,445 Long-term borrowings 2,145,468 — — — 2,145,468 Deferred tax liabilities 89,938 260,624 248,156 (2,284 ) 596,434 Pension and postretirement benefit liabilities 63,481 32,283 17,319 — 113,083 Noncurrent liability for uncertain tax positions 1,680 8,294 2,791 — 12,765 Notes payable and other amounts due to consolidated subsidiaries 2,240,361 2,125,535 202,670 (4,568,566 ) — Noncurrent contingent consideration — 121,116 11,089 — 132,205 Other liabilities 140,438 6,763 57,739 — 204,940 Total liabilities 5,798,250 3,108,570 796,265 (5,961,745 ) 3,741,340 Total shareholders' equity 2,433,981 4,993,222 2,549,638 (7,542,860 ) 2,433,981 Total liabilities and shareholders' equity $ 8,232,231 $ 8,101,792 $ 3,345,903 $ (13,504,605 ) $ 6,175,321 December 31, 2017 Parent Guarantor Non-Guarantor Eliminations Condensed (Dollars in thousands) ASSETS Current assets Cash and cash equivalents $ 37,803 $ 8,933 $ 286,822 $ — $ 333,558 Accounts receivable, net 2,414 57,818 280,980 4,663 345,875 Accounts receivable from consolidated subsidiaries 14,478 1,177,246 343,115 (1,534,839 ) — Inventories, net — 245,533 176,490 (26,279 ) 395,744 Prepaid expenses and other current assets 14,874 9,236 19,790 3,982 47,882 Prepaid taxes — — 5,748 — 5,748 Total current assets 69,569 1,498,766 1,112,945 (1,552,473 ) 1,128,807 Property, plant and equipment, net 2,088 213,663 167,248 — 382,999 Goodwill — 1,246,144 989,448 — 2,235,592 Intangibles assets, net — 1,355,275 1,028,473 — 2,383,748 Investments in consolidated subsidiaries 5,806,244 1,674,077 19,620 (7,499,941 ) — Deferred tax assets — — 6,071 (2,261 ) 3,810 Notes receivable and other amounts due from consolidated subsidiaries 2,452,101 2,231,832 — (4,683,933 ) — Other assets 31,173 6,397 8,966 — 46,536 Total assets $ 8,361,175 $ 8,226,154 $ 3,332,771 $ (13,738,608 ) $ 6,181,492 LIABILITIES AND EQUITY Current liabilities Current borrowings $ 36,625 $ — $ 50,000 $ — $ 86,625 Accounts payable 4,269 46,992 40,766 — 92,027 Accounts payable to consolidated subsidiaries 1,211,568 261,121 62,150 (1,534,839 ) — Accrued expenses 17,957 31,827 47,069 — 96,853 Current portion of contingent consideration — 74,224 — — 74,224 Payroll and benefit-related liabilities 21,145 44,009 42,261 — 107,415 Accrued interest 6,133 — 32 — 6,165 Income taxes payable 4,352 — 7,162 — 11,514 Other current liabilities 1,461 3,775 3,817 — 9,053 Total current liabilities 1,303,510 461,948 253,257 (1,534,839 ) 483,876 Long-term borrowings 2,162,927 — — — 2,162,927 Deferred tax liabilities 88,512 265,426 251,999 (2,261 ) 603,676 Pension and postretirement benefit liabilities 70,860 32,750 17,800 — 121,410 Noncurrent liability for uncertain tax positions 1,117 8,196 2,983 — 12,296 Notes payable and other amounts due to consolidated subsidiaries 2,155,146 2,320,611 208,176 (4,683,933 ) — Noncurrent contingent consideration — 186,923 10,989 — 197,912 Other liabilities 148,572 7,850 12,442 — 168,864 Total liabilities 5,930,644 3,283,704 757,646 (6,221,033 ) 3,750,961 Total shareholders' equity 2,430,531 4,942,450 2,575,125 (7,517,575 ) 2,430,531 Total liabilities and shareholders' equity $ 8,361,175 $ 8,226,154 $ 3,332,771 $ (13,738,608 ) $ 6,181,492
Condensed Consolidating Statements of Cash Flows	TELEFLEX INCORPORATED AND SUBSIDIARIES CONDENSED CONSOLIDATING STATEMENTS OF CASH FLOWS Six Months Ended July 1, 2018 Parent Guarantor Non-Guarantor Eliminations Condensed (Dollars in thousands) Net cash (used in) provided by operating activities from continuing operations $ (165,764 ) $ 253,365 $ 164,356 $ (70,373 ) $ 181,584 Cash flows from investing activities of continuing operations: Expenditures for property, plant and equipment (795 ) (16,602 ) (20,607 ) — (38,004 ) Proceeds from sale of investments 22,944 — — (22,944 ) — Payments for businesses and intangibles acquired, net of cash acquired — 1,404 (23,854 ) — (22,450 ) Net cash provided by (used in) investing activities from continuing operations 22,149 (15,198 ) (44,461 ) (22,944 ) (60,454 ) Cash flows from financing activities of continuing operations: Reduction in borrowings (18,500 ) — — — (18,500 ) Debt extinguishment, issuance and amendment fees (188 ) — — — (188 ) Net proceeds from share based compensation plans and the related tax impacts 9,800 — — — 9,800 Payments for contingent consideration — (62,574 ) — — (62,574 ) Dividends paid (30,938 ) — — — (30,938 ) Intercompany transactions 196,888 (171,900 ) (47,932 ) 22,944 — Intercompany dividends paid — — (70,373 ) 70,373 — Net cash provided by (used in) financing activities from continuing operations 157,062 (234,474 ) (118,305 ) 93,317 (102,400 ) Cash flows from discontinued operations: Net cash used in operating activities (464 ) — — — (464 ) Net cash used in discontinued operations (464 ) — — — (464 ) Effect of exchange rate changes on cash and cash equivalents — — (5,520 ) — (5,520 ) Net increase (decrease) in cash and cash equivalents 12,983 3,693 (3,930 ) — 12,746 Cash and cash equivalents at the beginning of the period 37,803 8,933 286,822 — 333,558 Cash and cash equivalents at the end of the period $ 50,786 $ 12,626 $ 282,892 $ — $ 346,304 Six Months Ended July 2, 2017 Parent Guarantor Non-Guarantor Eliminations Condensed (Dollars in thousands) Net cash (used in) provided by operating activities from continuing operations $ (121,726 ) $ 232,874 $ 148,460 $ (61,918 ) $ 197,690 Cash flows from investing activities of continuing operations: Expenditures for property, plant and equipment (173 ) (19,760 ) (16,900 ) — (36,833 ) Proceeds from sale of assets — — 6,332 — 6,332 Payments for businesses and intangibles acquired, net of cash acquired (975,524 ) — (17,935 ) — (993,459 ) Net cash used in investing activities from continuing operations (975,697 ) (19,760 ) (28,503 ) — (1,023,960 ) Cash flows from financing activities of continuing operations: Proceeds from new borrowings 1,194,500 — — — 1,194,500 Reduction in borrowings (228,273 ) — — — (228,273 ) Debt extinguishment, issuance and amendment fees (19,114 ) — — — (19,114 ) Net proceeds from share based compensation plans and the related tax impacts 1,305 — — — 1,305 Payments for contingent consideration — (153 ) — — (153 ) Dividends paid (30,590 ) — — — (30,590 ) Intercompany transactions 222,684 (203,029 ) (19,655 ) — — Intercompany dividends paid — — (61,918 ) 61,918 — Net cash provided by (used in) financing activities from continuing operations 1,140,512 (203,182 ) (81,573 ) 61,918 917,675 Cash flows from discontinued operations: Net cash used in operating activities (961 ) — — — (961 ) Net cash used in discontinued operations (961 ) — — — (961 ) Effect of exchange rate changes on cash and cash equivalents — — 41,981 — 41,981 Net increase in cash and cash equivalents 42,128 9,932 80,365 — 132,425 Cash and cash equivalents at the beginning of the period 14,571 1,031 528,187 — 543,789 Cash and cash equivalents at the end of the period $ 56,699 $ 10,963 $ 608,552 $ — $ 676,214

New accounting standards (Detai

New accounting standards (Details) - USD ($) $ in Millions	Jul. 01, 2018	Jan. 01, 2018
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Contract with customer, reverse for returns and allowances	$ 4.2
Accounting Standards Update 2016-16 [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cumulative effect of change on equity		$ 1.8
Difference between Revenue Guidance in Effect before and after Topic 606 [Member] | Accounting Standards Update 2014-09 [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Retained Earnings (Accumulated Deficit)		$ 1.2

Net revenues (Details)

Net revenues (Details) - USD ($) $ in Millions	6 Months Ended
	Jul. 01, 2018	Jul. 02, 2017
Concentration Risk [Line Items]
Reserve for returns and allowances	$ 4.2	$ 4.5
Reserve for the customer incentive programs, including distributor rebates	$ 13.6	$ 10.7
Sales Revenue, Net | Hospitals And Healthcare Providers | Customer Concentration Risk
Concentration Risk [Line Items]
Percentage of total revenue	87.00%
Sales Revenue, Net | Other Medical Device Manufacturers | Customer Concentration Risk
Concentration Risk [Line Items]
Percentage of total revenue	9.00%
Sales Revenue, Net | Home Care Providers | Customer Concentration Risk
Concentration Risk [Line Items]
Percentage of total revenue	4.00%

Net revenues Other revenues (De

Net revenues Other revenues (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jul. 01, 2018	Jul. 02, 2017	Jul. 01, 2018	Jul. 02, 2017
Revenue, Major Customer [Line Items]
Net revenues	$ 609,866	$ 528,613	$ 1,197,096	$ 1,016,494
Vascular access
Revenue, Major Customer [Line Items]
Net revenues	140,604	133,323	284,845	263,345
Anesthesia
Revenue, Major Customer [Line Items]
Net revenues	89,810	85,938	175,229	167,143
Interventional
Revenue, Major Customer [Line Items]
Net revenues	77,179	68,425	148,858	112,391
Surgical
Revenue, Major Customer [Line Items]
Net revenues	90,489	90,740	176,139	178,044
Interventional urology
Revenue, Major Customer [Line Items]
Net revenues	47,674	0	89,974	0
OEM
Revenue, Major Customer [Line Items]
Net revenues	52,594	45,132	98,448	88,478
Other (3)
Revenue, Major Customer [Line Items]
Net revenues	$ 111,516	$ 105,055	$ 223,603	$ 207,093

Acquisitions - Additional Infor

Acquisitions - Additional Information (Details) - USD ($) $ in Thousands	Jul. 09, 2018	Jun. 21, 2018	Oct. 02, 2017	Jul. 09, 2018	Jul. 01, 2018	Dec. 31, 2017	Feb. 17, 2017
Business Acquisition [Line Items]
Payments to acquire intangible assets		$ 20,600
Consideration transferred						$ 2,000,000
Contingent consideration liabilities					$ 242,659	$ 272,136
Aggregate milestone payment, maximum					335,200
Vascular Solutions, Inc.
Business Acquisition [Line Items]
Net assets acquired							$ 975,500
NeoTract
Business Acquisition [Line Items]
Cash payment to acquire business			$ 725,600
Business acquisition working capital adjustment			1,400
Contingent consideration liabilities					227,700
Aggregate milestone payment, maximum			$ 375,000		375,000
Milestone payment					$ 64,200
Subsequent Event | NeoTract
Business Acquisition [Line Items]
Milestone payment	$ 10,800			$ 75,000

Acquisitions - Pro Forma (Detai

Acquisitions - Pro Forma (Details) - Vascular Solutions, Inc. - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended	6 Months Ended
	Jul. 02, 2017	Jul. 02, 2017
Business Acquisition [Line Items]
Net revenue	$ 558,836	$ 1,092,154
Net income	$ 66,726	$ 103,833
Net Income, Basic earnings per common share (in USD per share)	$ 1.48	$ 2.31
Net Income, Diluted earnings per common share (in USD per share)	$ 1.43	$ 2.22
Basic, weighted average common shares outstanding (in shares)	44,996	44,945
Diluted, weighted average common shares outstanding (in shares)	46,818	46,716

Restructuring charges and imp42

Restructuring charges and impairment charges - Charges Recognized (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jul. 01, 2018	Jul. 02, 2017	Jul. 01, 2018	Jul. 02, 2017
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ 53,488	$ 870	$ 56,551	$ 13,815
Long-lived asset impairment charge	1,865		1,865
Restructuring and impairment charges	55,353	870	58,416	13,815
Termination benefits
Restructuring Cost and Reserve [Line Items]
Restructuring charges	52,919	612	55,576	13,361
Long-lived asset impairment charge	0		0
Restructuring and impairment charges	52,919		55,576
Other Restructuring costs
Restructuring Cost and Reserve [Line Items]
Restructuring charges	569	$ 258	975	454
Long-lived asset impairment charge	1,865		1,865
Restructuring and impairment charges	2,434		2,840
2018 Footprint realignment plan
Restructuring Cost and Reserve [Line Items]
Restructuring charges	52,474		52,474
2018 Footprint realignment plan | Termination benefits
Restructuring Cost and Reserve [Line Items]
Restructuring charges	52,345		52,345
2018 Footprint realignment plan | Other Restructuring costs
Restructuring Cost and Reserve [Line Items]
Restructuring charges	129		129
Other restructuring programs
Restructuring Cost and Reserve [Line Items]
Restructuring charges	1,014		1,587	1,491
Other restructuring programs | Termination benefits
Restructuring Cost and Reserve [Line Items]
Restructuring charges	574		1,032	1,147
Other restructuring programs | Other Restructuring costs
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ 440		555	344
2016 Footprint realignment plan
Restructuring Cost and Reserve [Line Items]
Restructuring charges			2,490	901
2016 Footprint realignment plan | Termination benefits
Restructuring Cost and Reserve [Line Items]
Restructuring charges			2,199	825
2016 Footprint realignment plan | Other Restructuring costs
Restructuring Cost and Reserve [Line Items]
Restructuring charges			$ 291	76
Vascular Solutions integration program
Restructuring Cost and Reserve [Line Items]
Restructuring charges				4,887
Vascular Solutions integration program | Termination benefits
Restructuring Cost and Reserve [Line Items]
Restructuring charges				4,853
Vascular Solutions integration program | Other Restructuring costs
Restructuring Cost and Reserve [Line Items]
Restructuring charges				34
2017 EMEA restructuring program
Restructuring Cost and Reserve [Line Items]
Restructuring charges				6,536
2017 EMEA restructuring program | Termination benefits
Restructuring Cost and Reserve [Line Items]
Restructuring charges				6,536
2017 EMEA restructuring program | Other Restructuring costs
Restructuring Cost and Reserve [Line Items]
Restructuring charges				$ 0

Restructuring charges and imp43

Restructuring charges and impairment charges - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jul. 01, 2018	Jul. 02, 2017	Jul. 01, 2018	Jul. 02, 2017	May 01, 2018
2018 Footprint realignment plan
Restructuring Cost and Reserve [Line Items]
Restructuring costs expected cash payment	$ 1		$ 1
Restructuring reserve	51.4		51.4
2018 Footprint realignment plan | Minimum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges					$ 102
2018 Footprint realignment plan | Minimum | Accelerated Depreciation And Other Costs
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges					40
2018 Footprint realignment plan | Maximum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges					133
2018 Footprint realignment plan | Maximum | Accelerated Depreciation And Other Costs
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges					$ 59
2016 Footprint realignment plan
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	43		43
Aggregate restructuring charges incurred	17.1		17.1
Restructuring reserve	6.3		6.3
2016 Footprint realignment plan | Accelerated Depreciation And Other Costs
Restructuring Cost and Reserve [Line Items]
Restructuring expenses	2	$ 2	3.3	$ 4.1
Aggregate restructuring charges incurred	18		18
2014 Footprint realignment plan
Restructuring Cost and Reserve [Line Items]
Restructuring expenses	27.9
Aggregate restructuring charges incurred	12.2		12.2
Restructuring reserve	3.9		3.9
2014 Footprint realignment plan | Accelerated Depreciation And Other Costs
Restructuring Cost and Reserve [Line Items]
Restructuring expenses	0.6	$ 0.5	1	$ 2.1
2014 Footprint realignment plan | Minimum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	46		46
2014 Footprint realignment plan | Maximum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	$ 51		$ 51

Restructuring charges and imp44

Restructuring charges and impairment charges - Charges By Segment (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jul. 01, 2018	Jul. 02, 2017	Jul. 01, 2018	Jul. 02, 2017
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ 53,488	$ 870	$ 56,551	$ 13,815
Vascular North America
Restructuring Cost and Reserve [Line Items]
Restructuring charges	202	353	523	1,081
Interventional North America
Restructuring Cost and Reserve [Line Items]
Restructuring charges	362	191	907	4,406
Anesthesia North America
Restructuring Cost and Reserve [Line Items]
Restructuring charges	91	564	125	811
EMEA
Restructuring Cost and Reserve [Line Items]
Restructuring charges	52,539	(412)	52,790	7,115
All Other
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ 294	$ 174	$ 2,206	$ 402

Restructuring charges and imp45

Restructuring charges and impairment charges - Cost Estimates By Major Type of Expense (Details) - 2018 Footprint realignment plan $ in Millions	May 01, 2018USD ($)
Minimum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	$ 102
Minimum | Termination benefits
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	60
Minimum | Other exit costs
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	2
Minimum | Special Termination Benefit And Other Restructuring
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	62
Minimum | Accelerated Depreciation And Other Costs
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	40
Maximum
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	133
Maximum | Termination benefits
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	70
Maximum | Other exit costs
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	4
Maximum | Special Termination Benefit And Other Restructuring
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	74
Maximum | Accelerated Depreciation And Other Costs
Restructuring Cost and Reserve [Line Items]
Expected restructuring charges	$ 59

Inventories, net (Detail)

Inventories, net (Detail) - USD ($) $ in Thousands	Jul. 01, 2018	Dec. 31, 2017
Inventory Disclosure [Abstract]
Raw materials	$ 103,005	$ 98,451
Work-in-process	63,386	62,381
Finished goods	239,037	234,912
Inventories, net	$ 405,428	$ 395,744

Goodwill and other intangible47

Goodwill and other intangible assets, net - Changes in carrying amount of goodwill, by reporting segment (Details) $ in Thousands	6 Months Ended
	Jul. 01, 2018USD ($)
Goodwill [Roll Forward]
Goodwill, beginning balance	$ 2,235,592
Goodwill related to acquisitions	579
Currency translation adjustment	(15,283)
Goodwill, ending balance	2,220,888
Vascular North America
Goodwill [Roll Forward]
Goodwill, beginning balance	264,869
Goodwill related to acquisitions	0
Currency translation adjustment	0
Goodwill, ending balance	264,869
Interventional North America
Goodwill [Roll Forward]
Goodwill, beginning balance	433,049
Goodwill related to acquisitions	422
Currency translation adjustment	(1,938)
Goodwill, ending balance	431,533
Anesthesia North America
Goodwill [Roll Forward]
Goodwill, beginning balance	157,289
Goodwill related to acquisitions	0
Currency translation adjustment	(395)
Goodwill, ending balance	156,894
Surgical North America
Goodwill [Roll Forward]
Goodwill, beginning balance	250,912
Goodwill related to acquisitions	0
Currency translation adjustment	0
Goodwill, ending balance	250,912
EMEA
Goodwill [Roll Forward]
Goodwill, beginning balance	494,548
Goodwill related to acquisitions	9
Currency translation adjustment	(9,836)
Goodwill, ending balance	484,721
Asia
Goodwill [Roll Forward]
Goodwill, beginning balance	209,200
Goodwill related to acquisitions	3
Currency translation adjustment	(2,352)
Goodwill, ending balance	206,851
OEM
Goodwill [Roll Forward]
Goodwill, beginning balance	4,883
Goodwill related to acquisitions	0
Currency translation adjustment	0
Goodwill, ending balance	4,883
All Other
Goodwill [Roll Forward]
Goodwill, beginning balance	420,842
Goodwill related to acquisitions	145
Currency translation adjustment	(762)
Goodwill, ending balance	$ 420,225

Goodwill and other intangible48

Goodwill and other intangible assets, net - Components of intangible assets (Details) - USD ($) $ in Thousands	Jul. 01, 2018	Dec. 31, 2017
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	$ 2,956,876	$ 2,964,632
Accumulated Amortization	(650,672)	(580,884)
In-process research and development
Finite-Lived Intangible Assets [Line Items]
In-process research and development	29,763	34,672
Accumulated Amortization	0	0
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets	1,016,254	1,023,837
Accumulated Amortization	(302,216)	(281,263)
Intellectual property
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets	1,295,555	1,287,487
Accumulated Amortization	(296,217)	(258,580)
Distribution rights
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets	23,570	23,697
Accumulated Amortization	(17,417)	(16,996)
Trade names
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets	568,227	571,510
Accumulated Amortization	(29,244)	(22,069)
Non-compete agreements
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets	23,507	23,429
Accumulated Amortization	$ (5,578)	$ (1,976)

Financial instruments - Additio

Financial instruments - Additional Information (Detail) - USD ($)	3 Months Ended		6 Months Ended
	Jul. 01, 2018	Jul. 02, 2017	Jul. 01, 2018	Jul. 02, 2017	Dec. 31, 2017
Spain, Italy, Portugal, and Greece
Derivatives Fair Value [Line Items]
Net revenues			$ 75,700,000	$ 64,500,000
Cash flow hedging
Derivatives Fair Value [Line Items]
Ineffectiveness related to derivatives	$ 0	$ 0	0	0
Foreign exchange contract | Designated as Hedging Instrument | Cash flow hedging
Derivatives Fair Value [Line Items]
Total notional amount for all open foreign currency forward contracts	113,800,000		113,800,000		$ 88,500,000
Foreign exchange contract | Not Designated as Hedging Instrument
Derivatives Fair Value [Line Items]
Loss related to currency forward contracts	1,400,000	$ 2,300,000	700,000	$ 3,100,000
Total notional amount for all open foreign currency forward contracts	$ 110,500,000		$ 110,500,000		$ 110,600,000

Financial instruments - Fair va

Financial instruments - Fair values of derivative instruments designated as hedging instruments (Details) - USD ($) $ in Thousands	Jul. 01, 2018	Dec. 31, 2017
Derivatives Fair Value [Line Items]
Total asset derivatives	$ 1,954	$ 1,221
Total liability derivatives	861	1,426
Foreign exchange contract | Prepaid expenses and other current assets
Derivatives Fair Value [Line Items]
Total asset derivatives	1,954	1,221
Foreign exchange contract | Other current liabilities
Derivatives Fair Value [Line Items]
Total liability derivatives	861	1,426
Foreign exchange contract | Designated as Hedging Instrument | Cash flow hedging | Prepaid expenses and other current assets
Derivatives Fair Value [Line Items]
Total asset derivatives	1,513	914
Foreign exchange contract | Designated as Hedging Instrument | Cash flow hedging | Other current liabilities
Derivatives Fair Value [Line Items]
Total liability derivatives	759	1,373
Foreign exchange contract | Not Designated as Hedging Instrument | Prepaid expenses and other current assets
Derivatives Fair Value [Line Items]
Total asset derivatives	441	307
Foreign exchange contract | Not Designated as Hedging Instrument | Other current liabilities
Derivatives Fair Value [Line Items]
Total liability derivatives	$ 102	$ 53

Financial instruments - Aggrega

Financial instruments - Aggregate accounts receivable, net of allowance for doubtful accounts (Details) - USD ($) $ in Thousands	Jul. 01, 2018	Dec. 31, 2017
Accounts, Notes, Loans and Financing Receivable [Line Items]
Allowance for doubtful accounts receivable	$ 9,525	$ 10,255
Allowance for doubtful accounts receivable, current	3,600	3,500
Spain, Italy, Portugal, and Greece
Accounts, Notes, Loans and Financing Receivable [Line Items]
Current and long-term trade accounts receivable in Greece, Italy, Spain and Portugal	$ 52,569	$ 49,054
Percentage of total net current and long-term trade accounts receivable - Greece, Italy, Spain and Portugal	15.00%	14.60%
Long-term portion of accounts receivable, net	$ 3,500	$ 3,300

Fair value measurement - Financ

Fair value measurement - Financial assets and liabilities carried at fair value measured on recurring basis (Details) - USD ($) $ in Thousands	Jul. 01, 2018	Dec. 31, 2017
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]
Investments in marketable securities	$ 9,272	$ 9,045
Derivative assets	1,954	1,221
Derivative liabilities	861	1,426
Contingent consideration liabilities	242,659	272,136
Quoted prices in active markets (Level 1)
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]
Investments in marketable securities	9,272	9,045
Derivative assets	0	0
Derivative liabilities	0	0
Contingent consideration liabilities	0	0
Significant other observable Inputs (Level 2)
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]
Investments in marketable securities	0	0
Derivative assets	1,954	1,221
Derivative liabilities	861	1,426
Contingent consideration liabilities	0	0
Significant unobservable Inputs (Level 3)
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]
Investments in marketable securities	0	0
Derivative assets	0	0
Derivative liabilities	0	0
Contingent consideration liabilities	$ 242,659	$ 272,136

Fair value measurement - Narrat

Fair value measurement - Narrative (Details) - USD ($) $ in Millions	Jul. 09, 2018	Jul. 09, 2018	Jul. 01, 2018	Oct. 02, 2017
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Aggregate milestone payment, maximum			$ 335.2
NeoTract
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Aggregate milestone payment, maximum			375	$ 375
Milestone payment			$ 64.2
Subsequent Event | NeoTract
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Milestone payment	$ 10.8	$ 75

Fair value measurement - Valuat

Fair value measurement - Valuation technique and inputs used in determining the fair value of contingent consideration (Details)	Jul. 01, 2018
Fair Value Disclosures [Abstract]
Contingent consideration, revenue volatility, percentage	22.30%

Fair value measurement - Reconc

Fair value measurement - Reconciliation of changes in financial liabilities measured on recurring basis (Details) $ in Thousands	6 Months Ended
	Jul. 01, 2018USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	$ 272,136
Additions	396
Payment	(64,372)
Revaluations	34,618
Translation adjustment	(119)
Ending balance	$ 242,659

Shareholders' equity - Addition

Shareholders' equity - Additional Information (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended		6 Months Ended
	Jul. 01, 2018	Jul. 02, 2017	Jul. 01, 2018	Jul. 02, 2017
Shareholders Equity [Line Items]
Warrant or right, outstanding (in shares)	197,274		197,274
Investment warrants, exercise price (in dollars per share)			$ 74.65
Intrinsic value of warrants	$ 38.5		$ 38.5
Weighted average antidilutive shares which were not included in the calculation of earnings per share	1,200,000
Equity Option
Shareholders Equity [Line Items]
Weighted average antidilutive shares which were not included in the calculation of earnings per share	2,000,000	700,000	700,000	600,000

Shareholders' equity - Reconcil

Shareholders' equity - Reconciliation of basic to diluted weighted average common shares outstanding (Details) - shares shares in Thousands	3 Months Ended		6 Months Ended
	Jul. 01, 2018	Jul. 02, 2017	Jul. 01, 2018	Jul. 02, 2017
Equity [Abstract]
Basic (in shares)	45,581	44,996	45,455	44,945
Dilutive effect of share-based awards (in shares)	0	866	1,052	843
Dilutive effect of convertible notes and warrants (in shares)	0	956	264	928
Diluted (in shares)	45,581	46,818	46,771	46,716

Shareholders' equity - Change i

Shareholders' equity - Change in accumulated other comprehensive income, net of tax (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jul. 01, 2018	Jul. 02, 2017	Jul. 01, 2018	Jul. 02, 2017
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning Balance			$ 2,430,531
Other comprehensive income (loss) before reclassifications			(43,226)	$ 114,682
Amounts reclassified from accumulated other comprehensive income	$ 1,258	$ 2,231	1,897	4,740
Net current-period other comprehensive income (loss)			(41,329)	119,422
Ending Balance	2,433,981		2,433,981
Cash Flow Hedges
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning Balance			340	(2,424)
Other comprehensive income (loss) before reclassifications			1,103	2,684
Amounts reclassified from accumulated other comprehensive income			(811)	2,477
Net current-period other comprehensive income (loss)			292	5,161
Ending Balance	632	2,737	632	2,737
Pension and Other Postretirement Benefit Plans
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning Balance			(138,808)	(136,596)
Other comprehensive income (loss) before reclassifications			188	(669)
Amounts reclassified from accumulated other comprehensive income	1,349	1,132	2,708	2,263
Net current-period other comprehensive income (loss)			2,896	1,594
Ending Balance	(135,912)	(135,002)	(135,912)	(135,002)
Foreign Currency Translation Adjustment
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning Balance			(126,623)	(299,697)
Other comprehensive income (loss) before reclassifications			(44,517)	112,667
Amounts reclassified from accumulated other comprehensive income			0	0
Net current-period other comprehensive income (loss)			(44,517)	112,667
Ending Balance	(171,140)	(187,030)	(171,140)	(187,030)
Accumulated Other Comprehensive (Loss) Income
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning Balance			(265,091)	(438,717)
Ending Balance	$ (306,420)	$ (319,295)	$ (306,420)	$ (319,295)

Shareholders' equity - Accumula

Shareholders' equity - Accumulated other comprehensive income into income expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jul. 01, 2018	Jul. 02, 2017	Jul. 01, 2018	Jul. 02, 2017
Accumulated Other Comprehensive Income (Loss) [Line Items]
Cost of goods sold	$ 265,088	$ 238,329	$ 521,048	$ 470,650
Total before tax	(7,024)	(90,458)	(68,197)	(128,138)
Taxes on income from continuing operations	9,576	12,095	15,818	9,426
Net of tax	2,552	(78,363)	(52,379)	(118,712)
Total reclassifications, net of tax	1,258	2,231	1,897	4,740
Actuarial losses
Accumulated Other Comprehensive Income (Loss) [Line Items]
Total before tax	1,734	1,727	3,480	3,453
Prior-service costs
Accumulated Other Comprehensive Income (Loss) [Line Items]
Total before tax	23	30	47	59
Pension and Other Postretirement Benefits Plans
Accumulated Other Comprehensive Income (Loss) [Line Items]
Total before tax	1,757	1,757	3,527	3,512
Tax benefit	(408)	(625)	(819)	(1,249)
Total reclassifications, net of tax	1,349	1,132	2,708	2,263
Reclassification out of Accumulated Other Comprehensive Income [Member] | Foreign exchange contract | Cash Flow Hedges
Accumulated Other Comprehensive Income (Loss) [Line Items]
Cost of goods sold	(118)	1,303	(951)	2,948
Total before tax	(118)	1,303	(951)	2,948
Taxes on income from continuing operations	27	(204)	140	(471)
Net of tax	$ (91)	$ 1,099	$ (811)	$ 2,477

Taxes on income from continui60

Taxes on income from continuing operations (Details)	3 Months Ended		6 Months Ended
	Jul. 01, 2018	Jul. 02, 2017	Jul. 01, 2018	Jul. 02, 2017
Income Tax Disclosure [Abstract]
Effective income tax rate	136.30%	13.40%	23.20%	7.40%

Pension and other postretirem61

Pension and other postretirement benefits (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jul. 01, 2018	Jul. 02, 2017	Jul. 01, 2018	Jul. 02, 2017
Pension
Defined Benefit Plan Disclosure [Line Items]
Service cost	$ 376	$ 720	$ 754	$ 1,437
Interest cost	3,718	3,789	7,439	7,574
Expected return on plan assets	(7,415)	(6,750)	(14,836)	(13,493)
Net amortization and deferral	1,695	1,691	3,403	3,381
Net benefits expense (income)	(1,626)	(550)	(3,240)	(1,101)
Other Postretirement Benefits
Defined Benefit Plan Disclosure [Line Items]
Service cost	52	75	104	149
Interest cost	378	379	756	757
Expected return on plan assets	0	0	0	0
Net amortization and deferral	62	66	124	131
Net benefits expense (income)	$ 492	$ 520	$ 984	$ 1,037

Commitments and contingent li62

Commitments and contingent liabilities (Detail) $ in Millions	6 Months Ended
	Jul. 01, 2018USD ($)
Loss Contingencies [Line Items]
Estimated litigation liability	$ 1.7
Minimum
Loss Contingencies [Line Items]
Estimated time fram over which accrued amounts may be paid out	15 years
Maximum
Loss Contingencies [Line Items]
Estimated time fram over which accrued amounts may be paid out	20 years
Accrued Liabilities
Loss Contingencies [Line Items]
Accrual for environmental loss contingencies	$ 1
Other Liability
Loss Contingencies [Line Items]
Accrual for environmental loss contingencies	$ 5.7

Segment information (Details)

Segment information (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jul. 01, 2018	Jul. 02, 2017	Jul. 01, 2018	Jul. 02, 2017
Revenues from External Customers and Long-Lived Assets [Line Items]
Net revenues	$ 609,866	$ 528,613	$ 1,197,096	$ 1,016,494
Operating profit	33,490	110,202	120,333	171,021
Operating Segments
Revenues from External Customers and Long-Lived Assets [Line Items]
Operating profit	108,148	126,519	221,192	217,100
Unallocated expenses
Revenues from External Customers and Long-Lived Assets [Line Items]
Operating profit	(74,658)	(16,317)	(100,859)	(46,079)
Vascular North America
Revenues from External Customers and Long-Lived Assets [Line Items]
Net revenues	80,062	78,796	163,110	157,807
Vascular North America | Operating Segments
Revenues from External Customers and Long-Lived Assets [Line Items]
Operating profit	24,636	18,472	49,298	36,762
Interventional North America
Revenues from External Customers and Long-Lived Assets [Line Items]
Net revenues	64,956	58,337	125,152	98,283
Interventional North America | Operating Segments
Revenues from External Customers and Long-Lived Assets [Line Items]
Operating profit	16,510	8,815	30,630	780
Anesthesia North America
Revenues from External Customers and Long-Lived Assets [Line Items]
Net revenues	50,490	49,081	101,055	97,288
Anesthesia North America | Operating Segments
Revenues from External Customers and Long-Lived Assets [Line Items]
Operating profit	14,716	20,056	32,049	33,360
Surgical North America
Revenues from External Customers and Long-Lived Assets [Line Items]
Net revenues	40,708	44,716	81,385	90,660
Surgical North America | Operating Segments
Revenues from External Customers and Long-Lived Assets [Line Items]
Operating profit	17,055	17,287	31,803	33,667
EMEA
Revenues from External Customers and Long-Lived Assets [Line Items]
Net revenues	153,415	138,469	313,285	272,043
EMEA | Operating Segments
Revenues from External Customers and Long-Lived Assets [Line Items]
Operating profit	26,535	23,594	58,305	44,904
Asia
Revenues from External Customers and Long-Lived Assets [Line Items]
Net revenues	72,413	65,998	130,657	116,166
Asia | Operating Segments
Revenues from External Customers and Long-Lived Assets [Line Items]
Operating profit	20,746	18,941	34,114	29,825
OEM
Revenues from External Customers and Long-Lived Assets [Line Items]
Net revenues	52,594	45,132	98,448	88,478
OEM | Operating Segments
Revenues from External Customers and Long-Lived Assets [Line Items]
Operating profit	13,552	10,337	22,568	19,458
All other
Revenues from External Customers and Long-Lived Assets [Line Items]
Net revenues	95,228	48,084	184,004	95,769
All other | Operating Segments
Revenues from External Customers and Long-Lived Assets [Line Items]
Operating profit	$ (25,602)	$ 9,017	$ (37,575)	$ 18,344

Segment information Total net r

Segment information Total net revenues by geographic region (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jul. 01, 2018	Jul. 02, 2017	Jul. 01, 2018	Jul. 02, 2017
Segment Reporting Information [Line Items]
Net revenues	$ 609,866	$ 528,613	$ 1,197,096	$ 1,016,494
United States
Segment Reporting Information [Line Items]
Net revenues	356,468	310,124	700,825	596,438
Europe
Segment Reporting Information [Line Items]
Net revenues	168,879	144,393	340,200	285,415
Asia
Segment Reporting Information [Line Items]
Net revenues	60,488	53,901	110,043	96,905
All Other
Segment Reporting Information [Line Items]
Net revenues	$ 24,031	$ 20,195	$ 46,028	$ 37,736

Condensed consolidating guara65

Condensed consolidating guarantor financial information - Additional Information (Detail) - Senior Notes	Jul. 01, 2018USD ($)
Condensed Financial Statements Captions [Line Items]
Ownership percentage	100.00%
5.25% Senior Notes due 2024
Condensed Financial Statements Captions [Line Items]
Debt instrument, face amount	$ 250,000,000
Debt instrument, stated interest rate	5.25%
4.875% Senior Notes Due 2026
Condensed Financial Statements Captions [Line Items]
Debt instrument, face amount	$ 400,000,000
Debt instrument, stated interest rate	4.875%
4.625% Senior Notes due 2027
Condensed Financial Statements Captions [Line Items]
Debt instrument, face amount	$ 500,000,000
Debt instrument, stated interest rate	4.625%

Condensed consolidating guara66

Condensed consolidating guarantor financial information - Income and Comprehensive Income (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jul. 01, 2018	Jul. 02, 2017	Jul. 01, 2018	Jul. 02, 2017
Condensed Income Statements, Captions [Line Items]
Net revenues	$ 609,866	$ 528,613	$ 1,197,096	$ 1,016,494
Cost of goods sold	265,088	238,329	521,048	470,650
Gross profit	344,778	290,284	676,048	545,844
Selling, general and administrative expenses	229,917	158,934	445,254	322,903
Research and development expenses	26,018	20,278	52,045	38,105
Restructuring and impairment charges	55,353	870	58,416	13,815
Income from continuing operations before interest, loss on extinguishment of debt and taxes	33,490	110,202	120,333	171,021
Interest, net	26,466	19,733	52,136	37,290
Loss on extinguishment of debt	0	11	0	5,593
Income from continuing operations before taxes	7,024	90,458	68,197	128,138
(Benefit) taxes on (loss) income from continuing operations	9,576	12,095	15,818	9,426
Equity in net income of consolidated subsidiaries	0	0	0	0
Income from continuing operations	(2,552)	78,363	52,379	118,712
Operating loss from discontinued operations	94	(566)	1,329	(848)
Benefit on loss from discontinued operations	38	(206)	20	(309)
Income (loss) from discontinued operations	56	(360)	1,309	(539)
Net income	(2,496)	78,003	53,688	118,173
Other comprehensive income	(124,019)	69,822	(41,329)	119,422
Comprehensive income	(126,515)	147,825	12,359	237,595
Eliminations
Condensed Income Statements, Captions [Line Items]
Net revenues	(107,717)	(106,984)	(219,915)	(211,061)
Cost of goods sold	(109,931)	(104,313)	(213,583)	(207,889)
Gross profit	2,214	(2,671)	(6,332)	(3,172)
Selling, general and administrative expenses	199	(39)	(330)	524
Research and development expenses	0	0	0	0
Restructuring and impairment charges	0	0	0	0
Income from continuing operations before interest, loss on extinguishment of debt and taxes	2,015	(2,632)	(6,002)	(3,696)
Interest, net	0	0	0	0
Loss on extinguishment of debt		0		0
Income from continuing operations before taxes	2,015	(2,632)	(6,002)	(3,696)
(Benefit) taxes on (loss) income from continuing operations	63	(1,123)	(1,103)	(599)
Equity in net income of consolidated subsidiaries	(46,736)	(158,062)	(198,472)	(283,705)
Income from continuing operations	(44,784)	(159,571)	(203,371)	(286,802)
Operating loss from discontinued operations	0	0	0	0
Benefit on loss from discontinued operations	0	0	0	0
Income (loss) from discontinued operations	0	0	0	0
Net income	(44,784)	(159,571)	(203,371)	(286,802)
Other comprehensive income	245,642	(137,501)	88,296	(240,806)
Comprehensive income	200,858	(297,072)	(115,075)	(527,608)
Parent Company
Condensed Income Statements, Captions [Line Items]
Net revenues	0	0	0	0
Cost of goods sold	0	0	0	0
Gross profit	0	0	0	0
Selling, general and administrative expenses	12,430	7,468	21,611	27,987
Research and development expenses	489	264	716	499
Restructuring and impairment charges	0	0	0	0
Income from continuing operations before interest, loss on extinguishment of debt and taxes	(12,919)	(7,732)	(22,327)	(28,486)
Interest, net	24,788	27,233	46,929	51,506
Loss on extinguishment of debt		11		5,593
Income from continuing operations before taxes	(37,707)	(34,976)	(69,256)	(85,585)
(Benefit) taxes on (loss) income from continuing operations	(13,218)	(14,378)	(26,410)	(35,711)
Equity in net income of consolidated subsidiaries	21,937	98,961	96,504	168,586
Income from continuing operations	(2,552)	78,363	53,658	118,712
Operating loss from discontinued operations	94	(566)	50	(848)
Benefit on loss from discontinued operations	38	(206)	20	(309)
Income (loss) from discontinued operations	56	(360)	30	(539)
Net income	(2,496)	78,003	53,688	118,173
Other comprehensive income	(124,019)	69,822	(41,329)	119,422
Comprehensive income	(126,515)	147,825	12,359	237,595
Guarantor Subsidiaries
Condensed Income Statements, Captions [Line Items]
Net revenues	391,304	338,620	770,723	654,263
Cost of goods sold	231,487	190,202	449,091	382,203
Gross profit	159,817	148,418	321,632	272,060
Selling, general and administrative expenses	139,565	95,171	270,479	189,214
Research and development expenses	18,818	13,594	38,186	24,780
Restructuring and impairment charges	2,545	1,335	3,453	6,709
Income from continuing operations before interest, loss on extinguishment of debt and taxes	(1,111)	38,318	9,514	51,357
Interest, net	1,078	(8,581)	4,009	(16,143)
Loss on extinguishment of debt		0		0
Income from continuing operations before taxes	(2,189)	46,899	5,505	67,500
(Benefit) taxes on (loss) income from continuing operations	7,486	13,386	13,909	19,297
Equity in net income of consolidated subsidiaries	24,457	58,861	101,333	114,663
Income from continuing operations	14,782	92,374	92,929	162,866
Operating loss from discontinued operations	0	0	0	0
Benefit on loss from discontinued operations	0	0	0	0
Income (loss) from discontinued operations	0	0	0	0
Net income	14,782	92,374	92,929	162,866
Other comprehensive income	(114,917)	68,127	(44,798)	117,531
Comprehensive income	(100,135)	160,501	48,131	280,397
Non-Guarantor Subsidiaries
Condensed Income Statements, Captions [Line Items]
Net revenues	326,279	296,977	646,288	573,292
Cost of goods sold	143,532	152,440	285,540	296,336
Gross profit	182,747	144,537	360,748	276,956
Selling, general and administrative expenses	77,723	56,334	153,494	105,178
Research and development expenses	6,711	6,420	13,143	12,826
Restructuring and impairment charges	52,808	(465)	54,963	7,106
Income from continuing operations before interest, loss on extinguishment of debt and taxes	45,505	82,248	139,148	151,846
Interest, net	600	1,081	1,198	1,927
Loss on extinguishment of debt		0		0
Income from continuing operations before taxes	44,905	81,167	137,950	149,919
(Benefit) taxes on (loss) income from continuing operations	15,245	14,210	29,422	26,439
Equity in net income of consolidated subsidiaries	342	240	635	456
Income from continuing operations	30,002	67,197	109,163	123,936
Operating loss from discontinued operations	0	0	1,279	0
Benefit on loss from discontinued operations	0	0	0	0
Income (loss) from discontinued operations	0	0	1,279	0
Net income	30,002	67,197	110,442	123,936
Other comprehensive income	(130,725)	69,374	(43,498)	123,275
Comprehensive income	$ (100,723)	$ 136,571	$ 66,944	$ 247,211

Condensed consolidating guara67

Condensed consolidating guarantor financial information - Balance Sheets (Details) - USD ($) $ in Thousands	Jul. 01, 2018	Dec. 31, 2017	Jul. 02, 2017	Dec. 31, 2016
Current assets
Cash and cash equivalents	$ 346,304	$ 333,558	$ 676,214	$ 543,789
Accounts receivable, net	359,119	345,875
Accounts receivable from consolidated subsidiaries	0	0
Inventories, net	405,428	395,744
Prepaid expenses and other current assets	52,105	47,882
Prepaid taxes	19,084	5,748
Assets held for sale	3,239	0
Total current assets	1,185,279	1,128,807
Property, plant and equipment, net	410,979	382,999
Goodwill	2,220,888	2,235,592
Intangible assets, net	2,306,204	2,383,748
Investments in consolidated subsidiaries	0	0
Deferred tax assets	2,386	3,810
Notes receivable and other amounts due from consolidated subsidiaries	0	0
Other assets	49,585	46,536
Total assets	6,175,321	6,181,492
Current liabilities
Current borrowings	86,875	86,625
Accounts payable	94,834	92,027
Accounts payable to consolidated subsidiaries	0	0
Accrued expenses	104,340	96,853
Current portion of contingent consideration	110,454	74,224
Payroll and benefit-related liabilities	89,669	107,415
Accrued interest	6,771	6,165
Income taxes payable	5,597	11,514
Other current liabilities	37,905	9,053
Total current liabilities	536,445	483,876
Long-term borrowings	2,145,468	2,162,927
Deferred tax liabilities	596,434	603,676
Pension and postretirement benefit liabilities	113,083	121,410
Noncurrent liability for uncertain tax positions	12,765	12,296
Notes payable and other amounts due to consolidated subsidiaries	0	0
Noncurrent contingent consideration	132,205	197,912
Other liabilities	204,940	168,864
Total liabilities	3,741,340	3,750,961
Total shareholders' equity	2,433,981	2,430,531
Total liabilities and shareholders' equity	6,175,321	6,181,492
Eliminations
Current assets
Cash and cash equivalents	0	0	0	0
Accounts receivable, net	4,992	4,663
Accounts receivable from consolidated subsidiaries	(1,389,792)	(1,534,839)
Inventories, net	(32,407)	(26,279)
Prepaid expenses and other current assets	3,982	3,982
Prepaid taxes	0	0
Assets held for sale	0
Total current assets	(1,413,225)	(1,552,473)
Property, plant and equipment, net	0	0
Goodwill	0	0
Intangible assets, net	0	0
Investments in consolidated subsidiaries	(7,520,530)	(7,499,941)
Deferred tax assets	(2,284)	(2,261)
Notes receivable and other amounts due from consolidated subsidiaries	(4,568,566)	(4,683,933)
Other assets	0	0
Total assets	(13,504,605)	(13,738,608)
Current liabilities
Current borrowings	0	0
Accounts payable	0	0
Accounts payable to consolidated subsidiaries	(1,389,792)	(1,534,839)
Accrued expenses	0	0
Current portion of contingent consideration	0	0
Payroll and benefit-related liabilities	0	0
Accrued interest	0	0
Income taxes payable	(1,103)	0
Other current liabilities	0	0
Total current liabilities	(1,390,895)	(1,534,839)
Long-term borrowings	0	0
Deferred tax liabilities	(2,284)	(2,261)
Pension and postretirement benefit liabilities	0	0
Noncurrent liability for uncertain tax positions	0	0
Notes payable and other amounts due to consolidated subsidiaries	(4,568,566)	(4,683,933)
Noncurrent contingent consideration	0	0
Other liabilities	0	0
Total liabilities	(5,961,745)	(6,221,033)
Total shareholders' equity	(7,542,860)	(7,517,575)
Total liabilities and shareholders' equity	(13,504,605)	(13,738,608)
Parent Company
Current assets
Cash and cash equivalents	50,786	37,803	56,699	14,571
Accounts receivable, net	2,328	2,414
Accounts receivable from consolidated subsidiaries	25,539	14,478
Inventories, net	0	0
Prepaid expenses and other current assets	14,657	14,874
Prepaid taxes	11,811	0
Assets held for sale	0
Total current assets	105,121	69,569
Property, plant and equipment, net	2,887	2,088
Goodwill	0	0
Intangible assets, net	0	0
Investments in consolidated subsidiaries	5,838,568	5,806,244
Deferred tax assets	0	0
Notes receivable and other amounts due from consolidated subsidiaries	2,255,108	2,452,101
Other assets	30,547	31,173
Total assets	8,232,231	8,361,175
Current liabilities
Current borrowings	36,875	36,625
Accounts payable	4,258	4,269
Accounts payable to consolidated subsidiaries	1,033,197	1,211,568
Accrued expenses	18,991	17,957
Current portion of contingent consideration	0	0
Payroll and benefit-related liabilities	15,958	21,145
Accrued interest	6,731	6,133
Income taxes payable	0	4,352
Other current liabilities	874	1,461
Total current liabilities	1,116,884	1,303,510
Long-term borrowings	2,145,468	2,162,927
Deferred tax liabilities	89,938	88,512
Pension and postretirement benefit liabilities	63,481	70,860
Noncurrent liability for uncertain tax positions	1,680	1,117
Notes payable and other amounts due to consolidated subsidiaries	2,240,361	2,155,146
Noncurrent contingent consideration	0	0
Other liabilities	140,438	148,572
Total liabilities	5,798,250	5,930,644
Total shareholders' equity	2,433,981	2,430,531
Total liabilities and shareholders' equity	8,232,231	8,361,175
Guarantor Subsidiaries
Current assets
Cash and cash equivalents	12,626	8,933	10,963	1,031
Accounts receivable, net	49,185	57,818
Accounts receivable from consolidated subsidiaries	1,004,686	1,177,246
Inventories, net	246,255	245,533
Prepaid expenses and other current assets	13,029	9,236
Prepaid taxes	0	0
Assets held for sale	3,239
Total current assets	1,329,020	1,498,766
Property, plant and equipment, net	233,105	213,663
Goodwill	1,245,806	1,246,144
Intangible assets, net	1,312,928	1,355,275
Investments in consolidated subsidiaries	1,661,595	1,674,077
Deferred tax assets	0	0
Notes receivable and other amounts due from consolidated subsidiaries	2,313,458	2,231,832
Other assets	5,880	6,397
Total assets	8,101,792	8,226,154
Current liabilities
Current borrowings	0	0
Accounts payable	53,913	46,992
Accounts payable to consolidated subsidiaries	288,217	261,121
Accrued expenses	33,421	31,827
Current portion of contingent consideration	110,454	74,224
Payroll and benefit-related liabilities	34,341	44,009
Accrued interest	0	0
Income taxes payable	0	0
Other current liabilities	33,609	3,775
Total current liabilities	553,955	461,948
Long-term borrowings	0	0
Deferred tax liabilities	260,624	265,426
Pension and postretirement benefit liabilities	32,283	32,750
Noncurrent liability for uncertain tax positions	8,294	8,196
Notes payable and other amounts due to consolidated subsidiaries	2,125,535	2,320,611
Noncurrent contingent consideration	121,116	186,923
Other liabilities	6,763	7,850
Total liabilities	3,108,570	3,283,704
Total shareholders' equity	4,993,222	4,942,450
Total liabilities and shareholders' equity	8,101,792	8,226,154
Non-Guarantor Subsidiaries
Current assets
Cash and cash equivalents	282,892	286,822	$ 608,552	$ 528,187
Accounts receivable, net	302,614	280,980
Accounts receivable from consolidated subsidiaries	359,567	343,115
Inventories, net	191,580	176,490
Prepaid expenses and other current assets	20,437	19,790
Prepaid taxes	7,273	5,748
Assets held for sale	0
Total current assets	1,164,363	1,112,945
Property, plant and equipment, net	174,987	167,248
Goodwill	975,082	989,448
Intangible assets, net	993,276	1,028,473
Investments in consolidated subsidiaries	20,367	19,620
Deferred tax assets	4,670	6,071
Notes receivable and other amounts due from consolidated subsidiaries	0	0
Other assets	13,158	8,966
Total assets	3,345,903	3,332,771
Current liabilities
Current borrowings	50,000	50,000
Accounts payable	36,663	40,766
Accounts payable to consolidated subsidiaries	68,378	62,150
Accrued expenses	51,928	47,069
Current portion of contingent consideration	0	0
Payroll and benefit-related liabilities	39,370	42,261
Accrued interest	40	32
Income taxes payable	6,700	7,162
Other current liabilities	3,422	3,817
Total current liabilities	256,501	253,257
Long-term borrowings	0	0
Deferred tax liabilities	248,156	251,999
Pension and postretirement benefit liabilities	17,319	17,800
Noncurrent liability for uncertain tax positions	2,791	2,983
Notes payable and other amounts due to consolidated subsidiaries	202,670	208,176
Noncurrent contingent consideration	11,089	10,989
Other liabilities	57,739	12,442
Total liabilities	796,265	757,646
Total shareholders' equity	2,549,638	2,575,125
Total liabilities and shareholders' equity	$ 3,345,903	$ 3,332,771

Condensed consolidating guara68

Condensed consolidating guarantor financial information - Cash Flows (Details) - USD ($) $ in Thousands	6 Months Ended
	Jul. 01, 2018	Jul. 02, 2017
Condensed Cash Flow Statements, Captions [Line Items]
Net cash (used in) provided by operating activities from continuing operations	$ 181,584	$ 197,690
Cash flows from investing activities of continuing operations:
Expenditures for property, plant and equipment	(38,004)	(36,833)
Proceeds from sale of investments	0	6,332
Payments for businesses and intangibles acquired, net of cash acquired	(22,450)	(993,459)
Net cash used in investing activities from continuing operations	(60,454)	(1,023,960)
Cash flows from financing activities of continuing operations:
Proceeds from new borrowings	0	1,194,500
Reduction in borrowings	(18,500)	(228,273)
Debt extinguishment, issuance and amendment fees	(188)	(19,114)
Net proceeds from share based compensation plans and the related tax impacts	9,800	1,305
Payments for contingent consideration	(62,574)	(153)
Dividends paid	(30,938)	(30,590)
Intercompany transactions	0	0
Intercompany dividends paid	0	0
Net cash provided by (used in) financing activities from continuing operations	(102,400)	917,675
Cash flows from discontinued operations:
Net cash used in operating activities	(464)	(961)
Net cash used in discontinued operations	(464)	(961)
Effect of exchange rate changes on cash and cash equivalents	(5,520)	41,981
Net increase in cash and cash equivalents	12,746	132,425
Cash and cash equivalents at the beginning of the period	333,558	543,789
Cash and cash equivalents at the end of the period	346,304	676,214
Eliminations
Condensed Cash Flow Statements, Captions [Line Items]
Net cash (used in) provided by operating activities from continuing operations	(70,373)	(61,918)
Cash flows from investing activities of continuing operations:
Expenditures for property, plant and equipment	0	0
Proceeds from sale of investments	(22,944)	0
Payments for businesses and intangibles acquired, net of cash acquired	0	0
Net cash used in investing activities from continuing operations	(22,944)	0
Cash flows from financing activities of continuing operations:
Proceeds from new borrowings		0
Reduction in borrowings	0	0
Debt extinguishment, issuance and amendment fees	0	0
Net proceeds from share based compensation plans and the related tax impacts	0	0
Payments for contingent consideration	0	0
Dividends paid	0	0
Intercompany transactions	22,944	0
Intercompany dividends paid	70,373	61,918
Net cash provided by (used in) financing activities from continuing operations	93,317	61,918
Cash flows from discontinued operations:
Net cash used in operating activities	0	0
Net cash used in discontinued operations	0	0
Effect of exchange rate changes on cash and cash equivalents	0	0
Net increase in cash and cash equivalents	0	0
Cash and cash equivalents at the beginning of the period	0	0
Cash and cash equivalents at the end of the period	0	0
Parent Company
Condensed Cash Flow Statements, Captions [Line Items]
Net cash (used in) provided by operating activities from continuing operations	(165,764)	(121,726)
Cash flows from investing activities of continuing operations:
Expenditures for property, plant and equipment	(795)	(173)
Proceeds from sale of investments	22,944	0
Payments for businesses and intangibles acquired, net of cash acquired	0	(975,524)
Net cash used in investing activities from continuing operations	22,149	(975,697)
Cash flows from financing activities of continuing operations:
Proceeds from new borrowings		1,194,500
Reduction in borrowings	(18,500)	(228,273)
Debt extinguishment, issuance and amendment fees	(188)	(19,114)
Net proceeds from share based compensation plans and the related tax impacts	9,800	1,305
Payments for contingent consideration	0	0
Dividends paid	(30,938)	(30,590)
Intercompany transactions	196,888	222,684
Intercompany dividends paid	0	0
Net cash provided by (used in) financing activities from continuing operations	157,062	1,140,512
Cash flows from discontinued operations:
Net cash used in operating activities	(464)	(961)
Net cash used in discontinued operations	(464)	(961)
Effect of exchange rate changes on cash and cash equivalents	0	0
Net increase in cash and cash equivalents	12,983	42,128
Cash and cash equivalents at the beginning of the period	37,803	14,571
Cash and cash equivalents at the end of the period	50,786	56,699
Guarantor Subsidiaries
Condensed Cash Flow Statements, Captions [Line Items]
Net cash (used in) provided by operating activities from continuing operations	253,365	232,874
Cash flows from investing activities of continuing operations:
Expenditures for property, plant and equipment	(16,602)	(19,760)
Proceeds from sale of investments	0	0
Payments for businesses and intangibles acquired, net of cash acquired	1,404	0
Net cash used in investing activities from continuing operations	(15,198)	(19,760)
Cash flows from financing activities of continuing operations:
Proceeds from new borrowings		0
Reduction in borrowings	0	0
Debt extinguishment, issuance and amendment fees	0	0
Net proceeds from share based compensation plans and the related tax impacts	0	0
Payments for contingent consideration	(62,574)	(153)
Dividends paid	0	0
Intercompany transactions	(171,900)	(203,029)
Intercompany dividends paid	0	0
Net cash provided by (used in) financing activities from continuing operations	(234,474)	(203,182)
Cash flows from discontinued operations:
Net cash used in operating activities	0	0
Net cash used in discontinued operations	0	0
Effect of exchange rate changes on cash and cash equivalents	0	0
Net increase in cash and cash equivalents	3,693	9,932
Cash and cash equivalents at the beginning of the period	8,933	1,031
Cash and cash equivalents at the end of the period	12,626	10,963
Non-Guarantor Subsidiaries
Condensed Cash Flow Statements, Captions [Line Items]
Net cash (used in) provided by operating activities from continuing operations	164,356	148,460
Cash flows from investing activities of continuing operations:
Expenditures for property, plant and equipment	(20,607)	(16,900)
Proceeds from sale of investments	0	6,332
Payments for businesses and intangibles acquired, net of cash acquired	(23,854)	(17,935)
Net cash used in investing activities from continuing operations	(44,461)	(28,503)
Cash flows from financing activities of continuing operations:
Proceeds from new borrowings		0
Reduction in borrowings	0	0
Debt extinguishment, issuance and amendment fees	0	0
Net proceeds from share based compensation plans and the related tax impacts	0	0
Payments for contingent consideration	0	0
Dividends paid	0	0
Intercompany transactions	(47,932)	(19,655)
Intercompany dividends paid	(70,373)	(61,918)
Net cash provided by (used in) financing activities from continuing operations	(118,305)	(81,573)
Cash flows from discontinued operations:
Net cash used in operating activities	0	0
Net cash used in discontinued operations	0	0
Effect of exchange rate changes on cash and cash equivalents	(5,520)	41,981
Net increase in cash and cash equivalents	(3,930)	80,365
Cash and cash equivalents at the beginning of the period	286,822	528,187
Cash and cash equivalents at the end of the period	$ 282,892	$ 608,552

Uncategorized Items - tfx-20180

Label	Element	Value
Cumulative Effect of New Accounting Principle in Period of Adoption	us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	$ 3,076,000
Retained Earnings [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption	us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	$ 3,076,000